



An Instrument for the Assessment of Diarrheal Severity in Community-Based Studies

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2014-004816
Article Type:	Research
Date Submitted by the Author:	08-Jan-2014
Complete List of Authors:	Lee, Gwenth; Johns Hopkins University, International Health Peñataro_Yori, Pablo; Johns Hopkins University, International Health; Asociación Benéfica Proyectos de Informática, Salud, Medicina, y Agricultura (A.B. PRISMA), Paredes_Olortegui, Maribel; Asociación Benéfica Proyectos de Informática, Salud, Medicina, y Agricultura (A.B. PRISMA), Caulfield, Laura; Johns Hopkins University, International Health Sack, David; Johns Hopkins University, International Health Fischer Walker, Christa; Johns Hopkins University, International Health Black, Robert; Johns Hopkins University, International Health Kosek, Margaret; Johns Hopkins University, International Health; Asociación Benéfica Proyectos de Informática, Salud, Medicina, y Agricultura (A.B. PRISMA),
Primary Subject Heading:	Global health
Secondary Subject Heading:	Epidemiology, Paediatrics
Keywords:	Gastrointestinal infections < GASTROENTEROLOGY, Tropical medicine < INFECTIOUS DISEASES, Community child health < PAEDIATRICS, Nutrition < TROPICAL MEDICINE

SCHOLARONE™
Manuscripts



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Title: An Instrument for the Assessment of Diarrheal Severity in Community-Based Studies

Authors: Gwenyth Lee, Pablo Peñataro_Yori, Maribel Paredes_Olortegui, Laura E. Caulfield, David A. Sack, Christa Fischer-Walker, Bob E. Black, Margaret Kosek*

Department of International Health, Johns Hopkins School of Public Health, Baltimore, MD 21205, USA, Asociación Benéfica Proyectos de Informática, Salud, Medicina, y Agricultura (A.B. PRISMA), Ramirez Hurtado 622, Iquitos, Peru.

Correspondence to:

* e-mail: mkosek@jhsph.edu
Assistant Professor
Johns Hopkins Bloomberg School of Public Health
615 N. Wolfe St E5545
Baltimore, MD21205
(410)-955-5932

For peer review only

1
2
3 **Abstract World Count:** 292
4

5 **Draft World Count:** 3,431
6
7
8
9

10 **Abstract:**
11

12 **Objective** Diarrhea is a significant contributor to morbidity and is among the leading causes of death of
13 children living in poverty. As such, the incidence, duration, and severity of diarrheal episodes in the
14 household are often key variables of interest in a variety of community-based studies. However, there
15 currently exists no means of defining diarrheal severity that are: (a) specifically designed and adapted
16 for community-based studies; (b) associated with poorer child outcomes; and (c) agreed upon by the
17 majority of researchers. Clinical severity scores do exist and are used in health care settings, but these
18 tend to focus on relatively severe dehydrating and dysenteric disease, require trained observation of the
19 child, and, given the variability of access and utilization of health care, fail to sufficiently describe the
20 spectrum of disease in the community setting.
21
22
23

24 **Design** Longitudinal cohort study
25

26 **Setting** Santa Clara de Nanay, a rural community in the Northern Peruvian Amazon
27
28

29 **Participants** 442 infants and children 0-72 months of age
30

31 **Main Outcome Measures** Change in weight over one month intervals and change in length/height over
32 9-month intervals
33
34

35 **Results** Diarrheal episodes with symptoms of fever, anorexia, vomiting, greater numbers of liquid stools
36 per day, and greater number of total stools per day, were associated with poorer weight gain compared
37 to episodes without these symptoms. An instrument to measure severity was constructed based upon
38 the duration of these symptoms over the course of a diarrheal episode.
39
40

41 **Conclusions** In order to address limitations of existing diarrheal severity scores in the context of
42 community-based studies, we propose an instrument comprised of diarrhea-associated symptoms easily
43 measured by community health workers and based on the association of these symptoms with poorer
44 child growth. This instrument can be used to test the impact of interventions on diarrheal disease
45 severity.
46
47
48
49
50

51 **Strengths and Limitations of the Study:**
52

53 -Intensive (three-times weekly) surveillance was used to capture symptoms of diarrheal severity in a
54 community-based context, and to relate these to weight gain.
55

56 -Symptoms associated with severe disease, including dehydration and rectal temperature, limit the
57 comparability of this instrument to existing diarrheal severity scores.
58
59
60

Introduction

Diarrhea is common cause of morbidity and mortality among children in the developing world (1). In addition to causing an estimated 0.75 million deaths per year (2), is estimated that the average child under five in the developing world will experience 2.9 episodes per year (3). The severity of these episodes is a common factor of interest in community-based epidemiological studies designed to test the impact of an intervention and/or quantify the burden of diarrheal disease (4).

Within the context of community-based studies diarrhea is defined as three or more loose stools per 24-hour period (5), prolonged diarrhea is diarrhea lasting between 7-13 days, and 'persistent' diarrhea as an episode of at least 14 days (6,7). These definitions were standardized in the early 1990s, leading to greater comparability between studies, and progress in the field.

Definitions of diarrheal severity, however, have remained variable (4). Clinical indicators of severity such as dehydration and dysentery (8) are associated with an acute risk of patient mortality and are used to guide therapy. These symptoms, in addition to need for hospitalization can define moderate to severe diarrhea among cases presenting for care at a healthcare center, but will not gradate between the majority of mild to moderate cases in the community (see **Figure 1**). As diarrhea case fatality rates decline, there is increasing interest in understanding the impact of mild-to-moderate disease on child health and development. For these episodes, there is a need for non-clinical measurement instruments adapted for use at a community level.

Several severity measurement instruments have been developed for classifying rotavirus diarrhea (9–11). However, these scores were not designed to differentiate severity of non-rotavirus diarrhea, which is less frequently associated with symptoms such as vomiting. Although rotavirus is the most frequently isolated pathogen among hospitalized diarrhea cases, there are other pathogens that are isolated more frequently in a typical community context. Furthermore, instruments that include hospitalization as a model input are problematic in settings where access to inpatient care facilities is heterogeneous, as can be observed in many low and middle-income settings.

Previous instruments included components such as rectal temperature and indexes of dehydration require either an invasive measurement or one that may be challenging to consistently measure across studies. These scales cannot be implemented in the context of community-based studies, where caregivers may not seek care for episodes of mild-to-moderate diarrhea and where surveillance is frequently bi-weekly or even weekly (12) and many episodes resolve in the interval between a study worker's regularly scheduled visits. While some studies have attempted to correct this problem through the creation of "modified" Vesikari scores (13,14), these scores were based on data from Canadian infants and HIV+ infants, respectively, making their findings less generalizable to the typical cases of pediatric diarrhea in the developing world.

Finally, the determination of severity in the formation of these instruments has generally been based on the empiric distribution of characteristics such as fever or dysentery associated with that particular cohort, rather than through association with morbidity (4). There are currently no instruments that

1
2
3 correlate on the high end to severe outcomes such as mortality and hospitalization, and on the middle-
4 to-low end with other, more frequently occurring adverse health outcomes.
5
6

7 Acute weight loss associated with a diarrheal episode puts a child at risk of becoming underweight
8 and/or wasted, outcomes associated with an increased risk of mortality (15,16), further infectious
9 disease (17) and future stunting (18). Poorer linear growth in early childhood is associated with long-
10 term negative outcomes including poorer cognitive development (19), adult work capacity and income
11 (20), and, for girls, poorer maternal health (15). Therefore, short-term weight gain and medium-to-long
12 term linear growth are appropriate functional outcomes through which to validate measures of disease
13 severity, and symptoms associated with poorer growth should be prioritized in the formation of
14 diarrheal severity scores.
15
16

17
18 Using data from a previously-established longitudinal cohort with a high incidence of diarrhea and
19 stunting and with standard community-based active surveillance measures, we evaluated the impact of
20 diarrheal-associated symptoms on short-term weight gain in the subsequent temporal period. From this,
21 we formed a diarrheal severity score to predict acute weight loss as well as depressed linear growth
22 over longer temporal windows. This instrument may be validated for use in community based studies,
23 clinical trials, and water, sanitation, and hygiene interventions.
24
25
26
27
28

29 **Methods**

30
31 Data were from a prospective, community-based study of 442 children 0-72 months of age living in the
32 community of Santa Clara, located 15 km southeast of Iquitos, Peru. The cohort and study design were
33 described previously (21,22); the overall objective was to explore the association between common
34 etiologies of diarrhea and early childhood growth. The work described here was a prespecified
35 secondary objective of the study.
36
37
38

39 From October 2002 – April 2006, participating families were visited three-times weekly by a trained
40 health promoter to document the number and consistency of stools passed by the child over the
41 previous 24-hour period, as well as other symptoms such as fever, anorexia, malaise, nausea, vomiting,
42 stomach pain, and the reported presence of blood and mucus in the child's feces. This generated a
43 continuous history of diarrheal disease over the surveillance period for each participating child (see
44 **Figure 2**). Anthropometry was collected monthly, and socioeconomic and demographic information
45 were collected during two community censuses before and during the study period. Diarrhea was
46 defined by three or more semi-liquid stools reported over a 24-hour period, with episodes separated by
47 at least three symptom-free days. Stool samples were collected as soon as possible after the case
48 definition for diarrhea was met, and not more than two days after the episode ended. Fecal blood and
49 fecal mucus, as reported by a lab technician, were also reported once per episode.
50
51
52
53

54 Symptoms associated with diarrhea were defined as having occurred during the diarrheal episode, if
55 they were present on any day of the episode. The duration of symptoms associated with diarrhea was
56
57
58
59
60

defined as the number of days of the episode upon which the symptom occurred. Symptoms which were present the day before or the day after an episode of diarrhea were not counted.

Since persistent diarrhea is regarded as a separate epidemiological phenomenon with effects on growth apart from those of shorter episodes(23), only episodes of <14 days were retained in the analysis. In this cohort less than two percent of episodes were persistent (>=14 days = 1.5% of all episodes).

Statistical Methods

The percentages of episodes associated with a given symptom by age were tabulated and compared (ANOVA), and correlations and partial correlations between the presence of symptoms during an episode, and the duration of symptoms during an episode were calculated. All analysis was performed using Stata 11 & 12 (Statacorp, College Station, TX, USA).

Effects of Specific Symptoms on short-term Weight Gain

The effect of the presence of a symptom (see list of symptoms in **Table 1**) on a child's weight gain was modeled using change in weight of the child before versus after the episode. Only intervals in which a diarrheal episode was present were include in the model (i.e. episodes of diarrhea were compared to each other, and were not compared with periods in which no diarrhea occurred). Only episodes that occurred between two instances of anthropometry one month apart were considered, i.e., episodes which overlapped an anthropometric measurement were discounted. In order to avoid instances in which acute dehydration might have impacted weight gain, episodes that ended less than two days before anthropometry were also excluded. When more than one episode occurred within the same one month interval, only the episode of longer duration was retained in the model, and the total number of episodes in the month was considered as a covariate in the analysis. Sensitivity analysis was performed to determine the effect of these omissions on model outputs.

$$Wt_{ij} - Wt_{i-1,j} = b_j + \beta_0 + \beta_1 D_{symptom} + \beta_2 \sin_{season} + \beta_3 \cos_{season} + \dots + \beta_4 \text{Age Term } 1 + \beta_5 \text{Age Term } 2 + \varepsilon_{ij} \quad \text{(Equation 1).}$$

The final model used to evaluate associations of symptoms with weight gain is shown in equation 1.

$D_{symptom}$ represents the presence or absence of a symptom during the episode or the duration, in days, of the symptom during an episode (Column 2 of **Table 3**). Seasonal variation in weight gain was modeled by adding the terms $\sin(\frac{2d\pi}{t})$ and $\cos(\frac{2d\pi}{t})$, where d is the day of the year, and t is 365 (24). Age Term 1 and Age Term 2 are fractional polynomials used to estimate the impact of age on monthly weight gain.

Formation of a Severity Score

Symptoms negatively associated with weight gain were categorized by duration and combined to form a severity score. When several symptoms were strongly correlated ($\rho > 0.40$), only the symptom that improved model fit was included in the severity score.

This score was then collapsed into three categories representing relatively mild, moderate, and severe diarrhea. The same model was then fit using the categorized variable. The unadjusted mean change in weight and weight for height Z score (WHZ) by severity category, and the adjusted one-month change in WHZ by severity category, were also estimated.

Effects of Specific Symptoms and Overall Severity on Linear Growth

In order to examine the relationship between individual symptoms and change in length/height, the cumulative incidence of episodes with and without each symptom was summed over nine-month intervals, and the effect of these episodes on linear growth (change in length/height) was modeled using the equation in Equation 2, where $D_{symptom_present}$ is the cumulative incidence of diarrheal episodes in which the symptom occurred, and $D_{symptom_absent}$ is the cumulative incidence of diarrheal episodes in which the symptom was absent, during the nine-month interval. The same seasonal terms and a set of fractional polynomial terms generated separately from those in the weight model were included. The models were also fitted with a child-level random intercept and a covariance structure that fixed a first-order autoregressive residual structure.

$$Ht_{ij} - Ht_{i-9,j} = b_j + \beta_0 + \beta_1 D_{symptom_present} + \beta_2 D_{symptom_absent} + \beta_3 \sin_{season} + \beta_4 \cos_{season} + \beta_5 AgeTerm_1 + \beta_6 AgeTerm_2 + \varepsilon_{ij} \quad (\text{Equation 2}).$$

The impact of episodes of varying severity, as categorized by the severity score developed above, was then tested similarly, using a model with three incidence terms, D_{mild} , $D_{moderate}$, and D_{severe} , representing the cumulative incidence of mild, moderate, and severe episodes in the nine-month interval, respectively. A similar model using nine-month change in HAZ as an outcome was used to test the effects of disease severity on HAZ.

Results

A total of 3,738 acute episodes were available for analysis. Of these, 2,461 were used in building the severity score (on the basis of being associated with anthropometry according to the criteria above, and with duplicate episodes in the same month discounted). Sensitivity analysis did not reveal any bias introduced by removing these episodes. Overall, 93.2% of the non-persistent episodes were associated with a lab result, of which 96.6% were collected within two days of the onset of the episode.

The symptoms considered in the analysis are reported in **Table 1**. The number of episodes associated with each symptom is shown in **Figure 3**. Most symptoms (all except anorexia and dysentery), were most common among the youngest children (≤ 2 years) and decreased in prevalence with age.

1
2
3 Correlations between the reporting of these symptoms during an episode ranged 0.018 to 0.643. The
4 strongest correlations were between maternal report of blood and lab-reported blood ($\rho=0.643$),
5 followed by nausea and vomiting ($\rho=0.642$), total depositions and liquid depositions ≥ 4 ($\rho=0.589$),
6 maternal report of blood and maternal report of mucus ($\rho=0.586$), malaise and stomach pain
7 ($\rho=0.550$), and malaise and anorexia ($\rho=0.427$). All other correlations were less than 0.4. The
8 correlations between the symptoms as categorized in the final severity score are reported below (**Table**
9 **2**).

13 *Effects of Specific Symptoms on short-term Weight Gain*

14
15 Anorexia, fever, malaise, vomiting and the maximum number of stools per 24/hour period, were all
16 associated with poorer weight gain in months associated with diarrhea ($p \leq 0.010$). These symptoms
17 were associated with 9.6 and 21.3 grams less weight gain per each day in the episode during which they
18 occurred (**Table 1**).

19
20 The number of days in an episode with ≥ 2 , ≥ 4 , ≥ 6 , and ≥ 8 liquid and or/semi-liquid stools were
21 strongly correlated with each other. Of these, the number of days with ≥ 4 liquid stools led to the
22 greatest improvement in model fit and was therefore retained for further analysis. Each day in which
23 ≥ 4 liquid stools were present was associated with 23.3 grams less weight gain (**Table 1**).

27 *Formation of a Severity Score*

28
29 In total, six factors were found to be predictive of poorer weight gain: anorexia, malaise, vomiting, fever,
30 the maximum number of stools per 24-hour period, and the number of days with 4 or more liquid per
31 24-hour period. Anorexia and malaise were strongly correlated ($\rho=0.432$), and therefore only
32 anorexia, which had the greater improvement in weight-model fit, was retained in the final severity
33 score. Other symptoms were more weakly correlated when categorized by duration ($\rho < 0.40$) (**Table**
34 **2**). These variables were categorized into 4 levels according to the duration of the symptom (**Table**
35 **3**). The severity score was built by summing these five categorical variables (**Table 3** and **Figures 2** and **4**).

36
37 Using this categorization process, episodes of moderate severity were found to predict 51.8g less weight
38 gain over one month than episodes of mild severity (reference value), and episodes of high severity
39 were found to predict 135.2 g less weight gain (**Table 4**). When change in WHZ was used as outcome,
40 moderate and severe episodes predicted a loss of 0.049 and 0.182 Z-scores over the month of the
41 episode, respectively (**Table 4**).

46 *Effects of Specific Symptoms and Overall Severity on Linear Growth*

47
48 Of all the symptoms tested, only dysentery, as defined by laboratory-observed blood in stool, was
49 independently predictive of poorer linear growth (results not shown). Because dysentery was not
50 included in the severity score, it was then added as an independent variable to the model testing the
51 impact of the severity score overall.

52
53 Incident episodes of low severity were not associated with poorer linear growth or changes in HAZ,
54 while each episode of moderate severity predicted 0.041cm less linear growth and 0.010 less in HAZ.

1
2
3 Episodes of the highest severity were also unassociated with changes in linear growth and HAZ over the
4 9 month period (Table 5).
5
6
7

8 9 Discussion

10
11 During diarrheal episodes, anorexia/malaise, fever, vomiting, the number of days with ≥ 4 liquid stools,
12 and the maximum number of depositions per 24/hour period, were the symptoms most strongly
13 associated with poorer weight gain. This suggests the prioritization of these symptoms in the formation
14 of a severity score to characterize mild-to-moderate diarrhea in community-based study settings.
15
16

17 Several symptoms of potential interest were not collected and therefore could not be included in our
18 analysis. Temperature, and the maximum number of instances of vomiting in a 24-hour period were not
19 collected, which limits our ability to compare our severity score to that of the 20-point Ruuska and
20 Vesikari score(11), and or the 24-point instrument proposed by Clark (9). Additionally, rectal
21 temperature and dehydration were not noted, so a comparison of the index proposed by Ericsson and
22 subsequently adapted by Jacobs et al could not be applied (25–27). These symptoms require the
23 observation of the child by a trained health worker daily, i.e. a visit to the child at the moment of illness
24 in addition to a caregiver's report. Our final severity score, which is based exclusively on information
25 extracted from the verbal report of a caregiver during twice weekly visits, may have greater utility in a
26 variety of community-based study designs where daily clinical assessments are not realistic. However,
27 an ability to compare our severity score to those based on episodes observed in a clinical setting would
28 be of methodological value(28).
29
30
31
32
33

34 Another weakness of our study was a relatively large number of "mild" episodes with a severity score of
35 0 or 1, and the relatively small number of "severe" episodes with a severity score >8 or above. Many
36 episodes were of one or two days in duration, associated with a low (3 or 4) number of maximum stools
37 per 24 hour period, and unassociated with any other symptom, and were therefore, difficult to
38 differentiate between. These observations are consistent with the best available estimates of the
39 proportion of categorization in mild, moderate, and severe episodes in the community setting (7).
40
41
42

43 In contrast, in the "high severity" category, there was a trend towards episodes of higher scores being
44 associated with greater weight loss, i.e. an episode of severity score 15 had a greater impact than one of
45 severity 8 (result not shown). However, because the number of episodes of greater severity was small,
46 they were grouped in a single category.
47
48

49 In this index, we assess duration of symptoms differently than previous scores. Instead of episode
50 duration being included as a separate variable, it was evaluated for inclusion for each symptom. We
51 believe this is important in evaluating enteric disease caused by a range of both invasive and non-
52 invasive pathogens where the illness syndrome is diverse. In contrast, previous severity scores have
53 been built around the ability of a symptom to discriminate between pathogens: for instance, rotavirus
54
55
56
57
58
59
60

1
2
3 diarrhea is typically associated with significant vomiting and frequent stools, but relatively less fever,
4 and the Vesakari index gives purging frequency and duration a high weight accordingly¹.
5
6

7 Dysentery, as defined by caregiver-reported or laboratory-technician reported visible blood, was not
8 found to be a predictor of immediate episode-associated weight loss. However, it was independently
9 predictive of poorer linear growth, a finding in agreement with other reports (29). The prevention of
10 dysenteric diarrhea, which is associated with progression to persistent diarrheal (23) and mortality (30)
11 merits prioritization. The importance of dysentery as a cause of linear growth faltering but not acute
12 weight loss suggests that multiple measurement tools for diarrheal severity may be useful. In addition
13 to acute weight loss and linear growth, factors such the likelihood of further infectious disease, the risk
14 of acute dehydration (8), and the risk of mortality, are important child health outcomes that should be
15 considered in score-building (**Figure 1**). The association between severity and the risk of hospitalization
16 should also be considered (31), although measures such as hospitalization, which are dependent upon
17 access and availability and not purely clinical need, vary according to local context and will need to be
18 assessed in a variety of settings (32).
19
20
21
22

23 Standardized and carefully considered measures of diarrheal severity are desirable in clinical trials,
24 intervention studies and descriptive community-based studies of diarrhea in the developing world (33),
25 and would improve understanding of the impact of disease control measures on morbidity burden. The
26 severity score we derived here is composed of simple components and allows for the meaningful
27 classification of a diarrheal disease episode based upon the most common adverse events associated
28 with diarrhea; depressed weight gain and poorer linear growth, an improvement over earlier scores
29 built empirically around symptom frequency. The collection of the input data for this score is highly
30 feasible and are likely available in many extant datasets; further validation could improve the estimates
31 of diarrhea severity and disease burden across epidemiologic settings.
32
33
34
35

36 **Contributors**

37
38 MK conceived and designed the study. MK, MPO, PPY designed the data collection tools, monitored
39 recruitment and data collection for the study, and supervised the study. PPY managed and cleaned the
40 data. GL designed and implemented the analysis, CFW, LEC, REB, and DAS provided guidance during the
41 analysis, and contributed to the interpretation of data. All authors helped write and critically review the
42 article, and all authors have approved the final version to be published and agree to be accountable for
43 all aspects of the work. MK and GL are the guarantors.
44
45
46

47 **Funding**

48
49 This work was supported by the National Institutes of Health [K01-TW05717 to M.K]. G.L. was supported
50 by a National Institutes of Health International Maternal and Child Health Training Grant [T32HD046405]
51 (PI Dr. Joanne Katz) and a Proctor and Gamble Doctoral Dissertation Fellowship, awarded by the Johns
52 Hopkins Bloomberg School of Public Health. The funders had no role in the collection, analysis, or
53 interpretation of the data.
54
55
56

57
58 ¹ With a maximum of 6 points related to vomiting and a maximum of 3 related to fever.
59
60

Ethical Approval

This study was approved by the Institutional Review boards of the Johns Hopkins Bloomberg School of Public Health, Baltimore, MD (IRB H.22.01.01.02.A), the US Naval Medical Research Center, Silver Springs, MD (IRB NMRCD.2002.0009), and Asociación Benéfica PRISMA, Lima, Peru (no IRB number). All participating families gave signed, informed consent before taking part in the study.

Competing Interests

We have read and understood the BMJ policy on declaration of interests and declare the following interests: None. All authors have completed the ICMJE uniform disclosure form at www.icjme.org/coi_disclosure.pdf (available on request from the corresponding author).

Declaration of Transparency

Gwenyth Lee confirms that this article is an honest, accurate and transparent account of the study reported, that no important aspects of the study have been omitted; and that any discrepancies from the study as planned have been explained.

Acknowledgements

We would like to thank Dr. William Pan for his contribution to the data analysis. Matilda Bustos Aricara, Victora Lopez Manuyama, Marla Judith Aricari Huanari, and Lleny Amasifuen Llerena, for their hard work and thoughtful contributions in the field. We would also like to thank Dr. S.T. Unt for his unwavering support of the team throughout.

Data sharing

Raw data used in the analysis is available on request from the corresponding author at mkosek@jhsph.edu. Statistical code is also available upon request.

References

1. Guerrant RL, Kosek M, Moore S, Lorntz B, Brantley R, Lima AAM. Magnitude and Impact of Diarrheal Diseases. Arch Med Res. 2002;33(4):351–5.

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
2. Liu L, Johnson HL, Cousens S, Perin J, Scott S, Lawn JE, et al. Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000. *Lancet*. Elsevier Ltd; 2012 Jun 9;379(9832):2151–61.
 3. Fischer-Walker CL, Perin J, Aryee MJ, Boschi-pinto C, Black RE. Diarrhea incidence in low- and middle-income countries in 1990 and 2010: a systematic review. *BMC Public Health*. BioMed Central Ltd; 2012;12(1):220.
 4. Johnston BC, Shamseer L, da Costa BR, Tsuyuki RT, Vohra S. Measurement issues in trials of pediatric acute diarrheal diseases: a systematic review. *Pediatrics*. 2010 Jul;126(1):e222–31.
 5. Baqui AH, Black RE, Yunus M, Hoque a R, Chowdhury HR, Sack RB. Methodological issues in diarrhoeal diseases epidemiology: definition of diarrhoeal episodes. *Int J Epidemiol*. 1991 Dec;20(4):1057–63.
 6. Stanton B, Clemens JD. Chronic diarrhoea: a methodologic basis for its apparent heterogeneity. *Trop Geogr Med*. 1989;41(2):100–7.
 7. Lamberti LM, Fischer-Walker CL, Black RE. Systematic review of diarrhea duration and severity in children and adults in low- and middle-income countries. *BMC Public Health*. 2012;12(1):276.
 8. Black RE, Merson M, Huq I, Alim A, Yunus M. Incidence and Severity of Rotavirus and Escherichia Coli Diarrhoea: Implications for Vaccine Development. *Lancet*. 1981;1978–80.
 9. Clark HF, Borian FE, Bell LM, Modesto K, Gouvea V, Plotkin SA. Protective effect of WC3 vaccine against rotavirus diarrhea in infants during a predominantly serotype 1 rotavirus season. *Vaccine*. 2012;158(3):570–87.
 10. Flores J, Perez-schael I, Gonzales M, Garcia D, Cunto W, Chanock RM, et al. Protection against severe rotavirus diarrhoea by rhesus rotavirus vaccine in Venezuelan infants. *Lancet*. 1986;329(8538):882–4.
 11. Ruuska T, Vesikari T. Rotavirus disease in Finnish children: use of numerical scores for clinical severity of diarrhoeal episodes. *Scan J Infect Dis*. 1990;22(3):259–67.
 12. Schmidt W-P, Arnold BF, Boisson S, Genser B, Luby SP, Barreto ML, et al. Epidemiological methods in diarrhoea studies — an update. *Int J Epidemiol*. 2011;40(6):1678–92.
 13. Freedman SB, Eltoroky M, Gorelick M. Evaluation of a gastroenteritis severity score for use in outpatient settings. *Pediatrics*. 2010 Jun;125(6):e1278–85.
 14. Mertz HR, Beck C, Dixon W, Esquivel A, Hays RD, Shapiro MF. Validation of a new measure of diarrhea. *Digest Dis Sci*. 1995 Sep;40(9):1873–82.
 15. Black RE, Allen LH, Bhutta ZA, Caulfield LE, de Onis M, Ezzati M, et al. Maternal and child undernutrition: global and regional exposures and health consequences. *Lancet*. Elsevier; 2008;371(9608):243–60.

16. Yoon P, RE B, Moulton H, Becker S. The effect of malnutrition on the risk of diarrheal and respiratory mortality in children < 2 y of age in Cebu, Philippines. *Am j Clin Nutr.* 1997 Apr;65(4):1070–7.
17. Guerrant RL, Schorling JB, McAuliffe JF, De Souza M a. Diarrhea as a cause and an effect of malnutrition: diarrhea prevents catch-up growth and malnutrition increases diarrhea frequency and duration. *Am J Trop Med Hyg. ASTMH;* 1992 Jul;47(1):28–35.
18. Richard SA, Black RE, Gilman RH, Guerrant RL, Kang G, Rasmussen ZA, et al. Wasting is associated with stunting in early childhood. *J Nutr.* 2012;142(7):1291–6.
19. Grantham-McGregor S. A review of studies of the effect of severe malnutrition on mental development. *J Nutr. Am Soc Nutrition;* 1995;125(8):2233.
20. Haas JD, Murdoch S, Rivera J, Martorell R. Early nutrition and later physical work capacity. *Nutr Rev.* 1996;54(2 Pt 2):S41.
21. Kosek M, Yori PP, Pan WK, Olortegui MP, Gilman RH, Perez J, et al. Epidemiology of highly endemic multiply antibiotic-resistant shigellosis in children in the Peruvian Amazon. *Pediatrics.* 2008 Sep;122(3):e541–9.
22. Lee G, Peñataro Yori P, Paredes Olortegui M, Pan W, Caulfield L, Gilman RH, et al. Comparative effects of vivax malaria, fever and diarrhoea on child growth. *Int J Epidemiol.* 2012;41(2):531–9.
23. Baqui AH, Black RE, Sack RB, Yunus MD, Siddique AK, Chowdhury HR. Epidemiological and clinical characteristics of acute and persistent diarrhoea in rural Bangladeshi children. *Acta Paediatr Suppl Suppl.* 1992;81(s383):15–21.
24. Stolwijk A, Straatman H, Zielhuis G. Studying seasonality by using sine and cosine functions in regression analysis. *J Epidemiol Commun H.* 1999 Apr;53(4):235–8.
25. Ericsson C, DuPont H, Sullivan P, Galindo E, Evans D, Evans D. Bicozamycin, A poorly absorbable antibiotic, effectively treats travelers diarrhea. *Ann Intern Med.* 1983;98(1):20.
26. Ericsson C, Johnson P, Dupont H, Morgan D, Bitsura A, de la Cabada F. Ciprofloxacin or Trimethoprim-Sulfamethoxazole as Initial Therapy for Travelers' Diarrhea: A Placebo-Controlled, Randomized Trial. *Ann Intern Med.* 1987;106:216–20.
27. Jacobs J, Gloyd S, Margarita Jimenez L, Crothers D. Treatment of Acute Childhood Diarrhea With Homeopathic Medicine: A Randomized Clinical Trial in Nicaragua. *Pediatrics.* 1994;93:719.
28. Givon-Lavi N, Greenberg D, Dagan R. Comparison between two severity scoring scales commonly used in the evaluation of rotavirus gastroenteritis in children. *Vaccine.* 2008;26(46):5798–801.
29. Alam DS, Marks GC, Baqui AH, Yunus M, Fuchs GJ. Association between clinical type of diarrhoea and growth of children under 5 years in rural Bangladesh. *Int J Epidemiol. IEA;* 2000 Oct;29(5):916–21.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
30. Victora CG, Huttly SRA, Fuchs SC, Barros FC, Garenne M, Leroy O, et al. International differences in clinical patterns of diarrhoeal deaths: a comparison of children from Brazil, Senegal, Bangladesh, and India. *J Diarrhoeal Dis Res.* 1993;11(1):25–9.
31. Walker CLF, Sack D, Black RE. Etiology of diarrhea in older children, adolescents and adults: a systematic review. *PLoS Negl Trop Dis.* 2010;4(8):e768.
32. Seidlein L Von, Kim DR, Ali M, Lee H, Wang X, Thiem VD, et al. A multicentre study of Shigella diarrhoea in six Asian countries: disease burden, clinical manifestations, and microbiology. *PLoS Med.* 2006;3(9):1556–69.
33. Sinha IP, Altman DG, Beresford MW, Boers M, Clarke M, Craig J, et al. Standard 5: selection, measurement, and reporting of outcomes in clinical trials in children. *Pediatrics.* 2012;129(S3):S146–S152.

28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Tables and Figures

Table 1: Association of Symptoms with Weight Gain

Caption: In the below model, age (as fractional polynomials, term1= $age^{-2} - 1.16$ and term2= $\ln(age) * age^{-2} - 0.08$), season (with sine/cosine terms), and an AR(1) covariance structure.

	Present in episode yes/no	duration
	change in weight (g) associated with symptom presence	change in weight (g) per days present
Anorexia	-49.1 (-8.8, -9.9) (p=0.014)	-12.4 (-22.4, -2.4) (p=0.015)
Blood in Stool (observed by Mother)	-1.8 (-61.4, 57.8) (p=0.952)	-1.3 (-26.2, 23.7) (p=0.920)
Blood in Stool (observed by lab tech)	10.6 (-72.5, 93.6) (p=0.803)	N/A
Fever	-46.9 (-88.1, -5.7) (p=0.026)	-17.4 (-33.4, -1.3) (p=0.034)
Nausea	-1.2 (-60.5, 58.2) (p=0.970)	-2.2 (-28.3, 23.8) (p=0.866)
Malaise	-49.4 (-84.9, -14.0) (p=0.006)	-9.5 (-17.8, -1.2) (p=0.025)

Mucus in Stool (observed by Mother)	-4.7 (-47.4, 38.0) (p=0.829)	0.1 (-14.4, 14.5) (p=0.994)
Mucus in Stool (observed by Lab tech)	0.3 (-34.4, 41.0) (p=0.863)	N/A
Stomach Pain	-13.9 (-48.8, 21.1) (p=0.427)	-5.4 (-13.3, 2.5) (p=0.179)
Vomiting	-56.9 (-109.2, -4.7) (p=0.033)	-23.2 (-46.0, -0.5) (p=0.046)
Four or more liquid stools in a 24/hr period	-44.0 (-80.6, -7.5) (p=0.018)	-23.6 (-37.6, -9.6) (p=0.001)
Maximum number of stools /24 hr period (continuous)	-9.9 (-18.0, -1.8) (p=0.016)	N/A
Episode Duration (per day - continuous)	-5.1 (-12.5, 2.4) (p=0.181)	N/A

Table 2: Correlations between symptoms retained in final severity score (N=3,738)

Symptoms are categorized according to the manner that they are included in the final score (0 days with symptom = 0, 1-2 days with symptom=1, 3-4 days with symptom=2, 5+ days with symptom=3).

	Anorexia	Fever	Vomiting	Liquid Stools	Max Stools
Days with Anorexia	1				
Days with Fever	0.27	1			
Days with Vomiting	0.24	0.24	1		
Days with ≥ 4 Liquid Stools	0.32	0.25	0.16	1	
Maximum stools/24hr period	0.25	0.27	0.27	0.34	1

Table 3: Severity Scorecard

Symptom	Category	Points
Diarrhea	>=3 liquid or semi-liquid stools per day, for 1-13 days, with gaps of no more than one day	
Fever	No Fever	+0
	Fever for 1-2 days	+1
	Fever for 3-4 days	+2
	Fever for 5+ days	+3
Anorexia	No Anorexia	+0
	Anorexia for 1-2 days	+1
	Anorexia for 3-4 days	+2
	Anorexia for 5+ days	+3
Vomiting	No Vomiting	+0
	Vomiting for 1-2 days	+1
	Vomiting for 3-4 days	+2
	Vomiting for 5+ days	+3
Liquid Stools	No days with >=4 liquid stools	+0
	1-2 days with >=4 liquid stools	+1
	3-4 days with >=4 liquid stools	+2
	5+ days with >=4 liquid stools	+3
Maximum number of stools in a 24 hour period during the episode	3	+0
	4-5	+1
	6-7	+2
	>=8	+3
TOTAL		0-15

Table 4: Association between Severity Score and change in Weight and Weight-for-Height

The association between incident episodes of diarrheal classified as low (score 0-1), medium severity (score 2-7) and high severity (score ≥ 8) on the change in weight and weight-for-height Z over 1-month intervals, is shown below. Age (same fractional polynomials as in symptom-specific models) and season (sine and cosine terms) were also adjusted for (beta coefficients not shown).

	1-month change in Weight (g)	1month change in WHZ (Z-score)
Low Severity	ref	ref
Medium Severity	-49.3 (-84.8, -13.8) (p=0.007)	-0.049 (-0.090, -0.008) (p=0.020)
High Severity	-133.0 (-223.2, -42.8) (p=0.004)	-0.180 (-285.2, -75.7) (p=0.001)

Table 5: Association between Severity Score and Linear Growth

The association between incident episodes of diarrheal classified as low (score 0-1), medium severity (score 2-7) and high severity (score ≥ 8) on the change in height and HAZ over 9-month intervals, is shown below. Age (fractional polynomials used to adjust for age in the height model are term1= $age^{-2} - 0.56$ and term3= $\ln(age) * age^3 - 2.41$), season (sine and cosine terms), stunting, and WHZ (categorized as >0 , 0 to -1, and <-1) were also adjusted for (beta coefficients not shown). In the HAZ model, fractional polynomials for age are $age^{-2} - 1.80$ and $= \ln(age) * age^2 - 0.53$.

	9mo change in Ht (cm)	9mo change in HAZ (Z-score)
Low-severity episodes (incidence)	-0.021 (-0.043, 0.001) (p=0.057)	-0.004 (-0.11, 0.003) (p=0.299)
Medium-severity episodes	-0.041(-0.065, -0.016) (p=0.001)	-0.010 (-0.19, -0.001) (p=0.022)
High-severity episodes	0.003 (-0.069, 0.074) (p=0.936)	-0.011 (-0.036,0.015) (p=0.423)
Episodes of dysentery	-0.113 (-0.189, -0.038) (p=0.003)	-0.034 (-0.062, -0.007) (p=0.013)

1
2
3 **Figure 1: Conceptual Diagram of Idealized Severity Score**
4
5
6
7

8 **Figure 2: Example of Severity Score Applied to an Episode:** A 6-day episode with fever on 3 days (+2),
9 anorexia on 0 days (+0), vomiting on 1 day (+1), a maximum total number of stools/day of 6 (+2) and a
10 total of 3 days with 4 or more liquid stools (+2) = total severity score of 7.
11
12

13
14
15 **Figure 3: Distribution of Symptoms**
16

17 Out of all episodes (n=3,738)
18
19
20

21 **Figure 4:** Histogram of severity score distribution. The y-axis (frequency) indicates the number of
22 episodes assigned to the score (N= 3,738).
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation
Title and abstract	1	<p>(a) Indicate the study's design with a commonly used term in the title or the abstract</p> <p><i>The phrase 'Community-Based Studies' is used in the title, and 'cohort study' is used in the abstract to describe the study's design.</i></p> <hr/> <p>(b) Provide in the abstract an informative and balanced summary of what was done and what was found</p> <p>√</p>
Introduction		
Background/rationale	2	<p>Explain the scientific background and rationale for the investigation being reported</p> <p><i>Please see introduction.</i></p>
Objectives	3	<p>State specific objectives, including any prespecified hypotheses</p> <p><i>"the overall objective was to explore the association between common etiologies of diarrhea and early childhood growth. The work described here was a prespecified secondary objective of the study."</i></p>
Methods		
Study design	4	<p>Present key elements of study design early in the paper</p> <p>√</p>
Setting	5	<p>Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection</p> <p><i>Information about the period of recruitment, exposure, and follow-up are mentioned, however, they have been reported in greater detail in previous published reports.</i></p>
Participants	6	<p>(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up</p> <p><i>Information about eligibility, sources, and methods of selection have been reported in detail in previous published reports.</i></p> <hr/> <p>(b) For matched studies, give matching criteria and number of exposed and unexposed</p> <p><i>N/A</i></p>
Variables	7	<p>Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable</p>

		√
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group
		√
Bias	9	Describe any efforts to address potential sources of bias <i>Attempts to avoid bias in the statistical analysis (sensitivity analysis) are described.</i>
Study size	10	Explain how the study size was arrived at <i>The original sample size was obtained based on the primary aim of estimating the association between enteropathogen-specific diarrheal episodes and growth.</i> <i>“A total of 3,738 acute episodes were available for analysis. Of these, 2,461 were used in building the severity score (on the basis of being associated with anthropometry according to the criteria above, and with duplicate episodes in the same month discounted).”</i>
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why <i>Certain variables (symptoms) that went into the formation of a diarrheal severity score were grouped on the basis of high correlation ($p > 0.40$); with only the variable that lead to the greatest improvement in model fit retained in the score.</i>
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding <i>As described above, variables that were strongly correlated were not co-included in the formation of the described severity score. Since the outcome of interest was growth (weight and height velocity), age and season were accounted for as co-variates.</i> <hr/> (b) Describe any methods used to examine subgroups and interactions <i>No subgroups were considered; mixed-effects models were used to account for correlation between episodes from the same child.</i> <hr/> (c) Explain how missing data were addressed <i>The data relevant to this analysis was essentially complete.</i> <hr/> (d) If applicable, explain how loss to follow-up was addressed

Not highly applicable to this analysis

(e) Describe any sensitivity analyses

Sensitivity analysis was performed to determine the effect of the omission of certain episodes on model outcomes, this is mentioned.

Results

Participants 13* (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed

The number of total children is mentioned, greater details have been reported elsewhere.

(b) Give reasons for non-participation at each stage

Loss to follow up during the cohort was low, the breakdown of reasons for lost to follow up have been reported elsewhere.

(c) Consider use of a flow diagram

Descriptive data 14* (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders

This has been reported in great detail in other reports, and so we have chosen to limit the repetition of this data.

(b) Indicate number of participants with missing data for each variable of interest

N/A- missingness is negligible as the unit of analysis is the diarrheal episode, however, we are happy to include greater details in this report as well if it is desirable.

(c) Summarise follow-up time (eg, average and total amount)

This has been reported elsewhere. (In order to limit the length of the manuscript we have attempted not to duplicate previously reported information, especially as, in this report, the unit of analysis was the diarrheal episode, rather than the child. However, in all cases, we are happy to include greater details in this report as well if it is desirable.)

Outcome data 15* Report numbers of outcome events or summary measures over time

“A total of 3,738 acute episodes were available for analysis. Of these, 2,461 were used in building the severity score (on the basis of being associated with anthropometry according to the criteria above, and with duplicate episodes in the same month discounted).”

Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and


1			their precision (eg, 95% confidence interval). Make clear which confounders were
2			adjusted for and why they were included
3			
4			<i>In all instances, estimates were adjusted for age and seasonal effects.</i>
5			
6			
7			(b) Report category boundaries when continuous variables were categorized
8			
9			√
10			
11			
12			(c) If relevant, consider translating estimates of relative risk into absolute risk for a
13			meaningful time period
14			
15			<i>N/A</i>
16			
17			
18	Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and
19			sensitivity analyses
20			
21			<i>These are reported.</i>
22			
23			
24			
25	Discussion		
26	Key results	18	Summarise key results with reference to study objectives
27			
28			√
29			
30			
31			
32	Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or
33			imprecision. Discuss both direction and magnitude of any potential bias
34			
35			<i>Limitations of the study are discussed.</i>
36			
37			
38			
39	Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations,
40			multiplicity of analyses, results from similar studies, and other relevant evidence
41			
42			√
43			
44			
45	Generalisability	21	Discuss the generalisability (external validity) of the study results
46			
47			√
48			
49			
50	Other information		
51	Funding	22	Give the source of funding and the role of the funders for the present study and, if
52			applicable, for the original study on which the present article is based
53			
54			
55			√
56			
57			

*Give information separately for exposed and unexposed groups.

1 **Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and
2 published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely
3 available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at
4 <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is
5 available at <http://www.strobe-statement.org>.
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Study Type	Community Setting		Healthcare Setting	
Type of diarrhea study will find	Mild	Moderate	Severe	
Episodes can be gradated by symptoms such as:	stomach pain, anorexia	Moderate dehydration, dysentery	Severe dehydration, need for IV hydration	
"Severity index" should correlate to:	Poorer growth, risk of MN deficiency, risk of future illness		Risk of short-term mortality	

Conceptual Diagram of Idealized Severity Score
165x119mm (96 x 96 DPI)


View only

	Sun	Mon	Tues	Wed	Thurs	Fri	Sat
Fever	no	YES	YES	YES	no	no	no
Anorexia	no	no	no	no	no	no	no
Vomiting	no	no	YES	no	no	no	no
Total Number of stools	3	4	4	5	6	3	2
Total number of Liquid stools	0	0	4	4	4	0	0

Example of Severity Score Applied to an Episode: A 6-day episode with fever on 3 days (+2), anorexia on 0 days (+0), vomiting on 1 day (+1), a maximum total number of stools/day of 6 (+2) and a total of 3 days with 4 or more liquid stools (+2) = total severity score of 7.

209x78mm (96 x 96 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Distribution of Symptoms: Out of all episodes (n=3,738)

154x103mm (96 x 96 DPI)

View only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Histogram of severity score distribution: The y-axis (frequency) indicates the number of episodes assigned to the score (N= 3,738).
254x142mm (96 x 96 DPI)

review only

BMJ Open

An Instrument for the Assessment of Diarrheal Severity based on a Longitudinal Community-Based Study

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2014-004816.R1
Article Type:	Research
Date Submitted by the Author:	29-Apr-2014
Complete List of Authors:	Lee, Gwennyth; Johns Hopkins University, International Health Peñataro_Yori, Pablo; Johns Hopkins University, International Health; Asociación Benéfica Proyectos de Informática, Salud, Medicina, y Agricultura (A.B. PRISMA), Paredes_Olortegui, Maribel; Asociación Benéfica Proyectos de Informática, Salud, Medicina, y Agricultura (A.B. PRISMA), Caulfield, Laura; Johns Hopkins University, International Health Sack, David; Johns Hopkins University, International Health Fischer Walker, Christa; Johns Hopkins University, International Health Black, Robert; Johns Hopkins University, International Health Kosek, Margaret; Johns Hopkins University, International Health; Asociación Benéfica Proyectos de Informática, Salud, Medicina, y Agricultura (A.B. PRISMA),
Primary Subject Heading:	Global health
Secondary Subject Heading:	Epidemiology, Paediatrics
Keywords:	Gastrointestinal infections < GASTROENTEROLOGY, Tropical medicine < INFECTIOUS DISEASES, Community child health < PAEDIATRICS, Nutrition < TROPICAL MEDICINE

SCHOLARONE™
Manuscripts



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Title: An Instrument for the Assessment of Diarrheal Severity based on a Longitudinal Community-Based Study

Authors: Gwennyth Lee, Pablo Peñataro_Yori, Maribel Paredes_Olortegui, Laura E. Caulfield, David A. Sack, Christa Fischer-Walker, Robert E. Black, Margaret Kosek*

Department of International Health, Johns Hopkins School of Public Health, Baltimore, MD 21205, USA, Asociación Benéfica Proyectos de Informática, Salud, Medicina, y Agricultura (A.B. PRISMA), Ramirez Hurtado 622, Iquitos, Peru.

Correspondence to:

* e-mail: mkosek@jhsph.edu
Assistant Professor
Johns Hopkins Bloomberg School of Public Health
615 N. Wolfe St E5545
Baltimore, MD21205
(410)-955-5932

1
2
3 **Abstract World Count:** 296
4

5 **Draft World Count:** 4,083
6
7
8
9

10 **Abstract:**
11

12 **Objective** Diarrhea is a significant contributor to morbidity and is among the leading causes of death of
13 children living in poverty. As such, the incidence, duration, and severity of diarrheal episodes in the
14 household are often key variables of interest in a variety of community-based studies. However, there
15 currently exists no means of defining diarrheal severity that are: (a) specifically designed and adapted
16 for community-based studies; (b) associated with poorer child outcomes; and (c) agreed upon by the
17 majority of researchers. Clinical severity scores do exist and are used in health care settings, but these
18 tend to focus on relatively moderate to severe dehydrating and dysenteric disease, require trained
19 observation of the child, and, given the variability of access and utilization of health care, fail to
20 sufficiently describe the spectrum of disease in the community setting.
21
22
23

24 **Design** Longitudinal cohort study
25

26 **Setting** Santa Clara de Nanay, a rural community in the Northern Peruvian Amazon
27
28

29 **Participants** 442 infants and children 0-72 months of age
30

31 **Main Outcome Measures** Change in weight over one month intervals and change in length/height over
32 9-month intervals
33
34

35 **Results** Diarrheal episodes with symptoms of fever, anorexia, vomiting, greater numbers of liquid stools
36 per day, and greater number of total stools per day, were associated with poorer weight gain compared
37 to episodes without these symptoms. An instrument to measure severity was constructed based upon
38 the duration of these symptoms over the course of a diarrheal episode.
39
40

41 **Conclusions** In order to address limitations of existing diarrheal severity scores in the context of
42 community-based studies, we propose an instrument comprised of diarrhea-associated symptoms easily
43 measured by community health workers and based on the association of these symptoms with poorer
44 child growth. This instrument can be used to test the impact of interventions on the burden of diarrheal
45 disease.
46
47
48
49
50

51 **Strengths and Limitations of the Study:**
52

53 -Intensive (three-times weekly) surveillance was used to capture symptoms of diarrheal severity in a
54 community-based context, and to relate these to weight gain.
55

56 -A lack of information about clinical signs associated with severe disease, including dehydration and
57 rectal temperature, limit the comparability of this instrument to existing diarrheal severity scores.
58
59
60

Introduction

Diarrhea is common cause of morbidity and mortality among children in the developing world (1). In addition to causing an estimated 0.75 million deaths per year (2), is estimated that the average child under five in the developing world will experience 2.9 episodes per year (3). The severity of these episodes is a common factor of interest in community-based epidemiological studies designed to test the impact of an intervention and/or quantify the burden of diarrheal disease (4).

Within the context of community-based studies diarrhea is defined as three or more loose stools per 24-hour period (5), prolonged diarrhea is diarrhea lasting between 7-13 days, and 'persistent' diarrhea as an episode of at least 14 days (6,7). These definitions were standardized in the early 1990s, leading to greater comparability between studies, and progress in the field.

Definitions of diarrheal severity, however, have remained variable (4). Clinical indicators of severity such as dehydration and dysentery (8) are associated with an acute risk of patient mortality and are used to guide therapy. These symptoms, in addition to need for hospitalization can define moderate to severe diarrhea among cases presenting for care at a healthcare center, but will not gradate between the majority of mild to moderate cases in the community (see **Figure 1**). As diarrhea case fatality rates decline, there is increasing interest in understanding the impact of mild-to-moderate disease on child health and development. For these episodes, there is a need for non-clinical measurement instruments adapted for use at a community level.

Several severity measurement instruments have been developed for classifying rotavirus diarrhea (9–11). However, these scores were not designed to differentiate severity of non-rotavirus diarrhea, which is less frequently associated with symptoms such as vomiting. Although rotavirus is the most frequently isolated pathogen among hospitalized diarrhea cases, there are other pathogens that are isolated more frequently in a typical community context. Furthermore, instruments that include hospitalization as a model input are problematic in settings where access to inpatient care facilities is heterogeneous, as can be observed in many low and middle-income settings.

Previous instruments have included components such as rectal temperature and indexes of dehydration require either an invasive measurement or one that may be challenging to consistently measure across studies. These scales cannot be implemented in the context of community-based studies, where caregivers may not seek care for episodes of mild-to-moderate diarrhea and where surveillance is frequently bi-weekly or weekly (12) and many episodes resolve in the interval between a study worker's regularly scheduled visits. While some studies have attempted to correct this problem through the creation of "modified" Vesikari scores (13,14), these scores were based on data from Canadian infants and HIV+ infants, respectively, making their findings less generalizable to the typical cases of pediatric diarrhea in the developing world.

Finally, the determination of severity in the formation of these instruments has generally been based on the empiric distribution of characteristics such as fever or dysentery associated with that particular cohort, rather than through association with morbidity (4). There are currently no instruments that

1
2
3 correlate on the high end to severe outcomes such as mortality and hospitalization, and on the middle-
4 to-low end with other, more frequently occurring adverse health outcomes.
5
6

7 Acute weight loss associated with a diarrheal episode puts a child at risk of becoming underweight
8 and/or wasted, outcomes associated with an increased risk of mortality (15,16), further infectious
9 disease (17) and future stunting (18). Poorer linear growth in early childhood is associated with long-
10 term negative outcomes including poorer cognitive development (19), adult work capacity and income
11 (20), and, for girls, poorer maternal health (15). Therefore, short-term weight gain and medium-to-long
12 term linear growth are appropriate functional outcomes through which to validate measures of disease
13 severity, and symptoms associated with poorer growth should be prioritized in the formation of
14 diarrheal severity scores.
15
16

17
18 Using data from a previously-established longitudinal cohort with a high incidence of diarrhea and
19 stunting and with standard community-based active surveillance measures, we evaluated the impact of
20 diarrheal-associated symptoms on short-term weight gain in the subsequent temporal period. From this,
21 we formed a diarrheal severity score to predict acute weight loss as well as depressed linear growth
22 over longer temporal windows. This instrument may be validated for use in community based studies,
23 clinical trials, and water, sanitation, and hygiene interventions.
24
25
26
27
28

29 **Methods**

30
31 Data were from a prospective, community-based study of 442 children 0-72 months of age living in the
32 community of Santa Clara, located 15 km southeast of Iquitos, Peru. The cohort and study design were
33 described previously (21,22); the overall objective was to explore the association between common
34 etiologies of diarrhea and early childhood growth. The work described here was a prespecified
35 secondary objective of the study.
36
37
38

39 From October 2002 – April 2006, participating families were visited three-times weekly by a trained
40 health promoter to document the number and consistency of stools passed by the child over the
41 previous 24-hour period, as well as other symptoms such as fever, anorexia, malaise, nausea, vomiting,
42 stomach pain, and the reported presence of blood and mucus in the child's feces. For example, malaise
43 was translated as "malestar general" and described to mothers as a lack of energy or irritability in the
44 child, and anorexia (translated as "recibe bien la comida") was described as the child's
45 willingness/eagerness to eat as usual. This generated a continuous history of diarrheal disease over the
46 surveillance period for each participating child. Anthropometry was collected monthly, and
47 socioeconomic and demographic information were collected during two community censuses before
48 and during the study period. Diarrhea was defined by three or more semi-liquid stools reported over a
49 24-hour period, with episodes separated by at least three symptom-free days. Stool samples were
50 collected as soon as possible after the case definition for diarrhea was met, and not more than two days
51 after the episode ended. Fecal blood and fecal mucus, as reported by a lab technician, were also
52 reported once per episode.
53
54
55
56
57
58
59
60

Symptoms associated with diarrhea were defined as having occurred during the diarrheal episode, if they were present on any day of the episode. The duration of symptoms associated with diarrhea was defined as the number of days of the episode upon which the symptom occurred. Symptoms which were present the day before or the day after an episode of diarrhea were not counted.

Since persistent diarrhea is regarded as a separate epidemiological phenomenon with effects on growth apart from those of shorter episodes (23), only episodes of <14 days were retained in the analysis. In this cohort less than two percent of episodes were persistent (≥ 14 days = 2.4% of all episodes).

Statistical Methods

The percentages of episodes associated with a given symptom by age were tabulated and compared (ANOVA), and correlations and partial correlations between the presence of symptoms during an episode, and the duration of symptoms during an episode were calculated. All analysis was performed using Stata 11 & Stata 12 (Statacorp, College Station, TX, USA).

Effects of Specific Symptoms on short-term Weight Gain

The effect of the presence of a symptom (see list of symptoms in **Table 1**) on a child's weight gain was modeled using change in weight of the child before versus after the episode. Only intervals in which a diarrheal episode was present were included in the model (i.e. episodes of diarrhea were compared to each other, and were not compared with periods in which no diarrhea occurred). Only episodes that occurred between two instances of anthropometry one month apart were considered, i.e., episodes which overlapped an anthropometric measurement were discounted. In order to avoid instances in which acute dehydration might have impacted weight gain, episodes that ended less than two days before anthropometry were also excluded. Rather than include the same one-month interval of anthropometry repeatedly within the model, when more than one episode occurred within the same one month interval, only the episode of longer duration was retained, and the total number of episodes in the month was considered as a covariate in the analysis. Sensitivity analysis was performed to determine the effect of these omissions on model outputs.

$$Wt_{ij} - Wt_{i-1,j} = b_j + \beta_0 + \beta_1 D_{symptom} + \beta_2 \sin_{season} + \beta_3 \cos_{season} + \dots + \beta_4 \text{Age Term } 1 + \beta_5 \text{Age Term } 2 + \varepsilon_{ij} \quad (\text{Equation 1}).$$

The final model used to evaluate associations of symptoms with weight gain is shown in equation 1.

$D_{symptom}$ represents the presence or absence of a symptom during the episode or the duration (in days) of the symptom during an episode (Column 2 of **Table 1**). Seasonal variation in weight gain was modeled by adding the terms $\sin\left(\frac{2d\pi}{t}\right)$ and $\cos\left(\frac{2d\pi}{t}\right)$, where d is the day of the year, and t is 365 (24). Age Term 1 and Age Term 2 are fractional polynomials used to estimate the impact of age on monthly weight gain. The models were also fitted with a child-level random intercept and a covariance

structure that fixed a first-order autoregressive residual structure to account for those instances in which a child experienced episodes of diarrhea over consecutive one-month intervals.

Formation of a Severity Score

Symptoms negatively associated with weight gain were categorized by duration and combined to form a severity score. In order to judge how many points should be given to symptoms of a given duration, models where duration was categorical were used to determine whether the association per day of the symptom on weight gain was additive, or whether there were threshold effects. After forming the score, sensitivity analysis was used to check that the inclusion of each additional component improved the overall model fit.

The score was then collapsed into three categories representing relatively mild, moderate, and severe diarrhea. The same model was then fit using the categorized variable. The unadjusted mean change in weight and weight for height Z score (WHZ) by severity category, and the adjusted one-month change in WHZ by severity category, were also estimated.

Effects of Specific Symptoms and Overall Severity on Linear Growth

In order to examine the relationship between individual symptoms and change in length/height, the cumulative incidence of episodes with and without each symptom was summed over nine-month intervals, and the effect of these episodes on linear growth (change in length/height) was modeled using the equation in Equation 2, where $D_{symptom_present}$ is the cumulative incidence of diarrheal episodes in which the symptom occurred, and $D_{symptom_absent}$ is the cumulative incidence of diarrheal episodes in which the symptom was absent, during the nine-month interval. The same seasonal terms and a set of fractional polynomial terms generated separately from those in the weight model were included. The models were also fitted with a child-level random intercept and a covariance structure that fixed a first-order autoregressive residual structure.

$$Ht_{ij} - Ht_{i-9,j} = b_j + \beta_0 + \beta_1 D_{symptom_present} + \beta_2 D_{symptom_absent} + \beta_3 \sin_{season} + \beta_4 \cos_{season} + \beta_5 AgeTerm_1 + \beta_6 AgeTerm_2 + \varepsilon_{ij} \quad \text{(Equation 2)}.$$

The impact of episodes of varying severity, as categorized by the severity score developed above, was then tested similarly, using a model with three incidence terms, D_{mild} , $D_{moderate}$, and D_{severe} , representing the cumulative incidence of mild, moderate, and severe episodes in the nine-month interval, respectively. A similar model using nine-month change in HAZ as an outcome was used to test the effects of disease severity on HAZ.

Results

1
2
3 A total of 3,915 acute episodes were available for analysis. Of these, 2,462 were used in building the
4 severity score (on the basis of being associated with anthropometry according to the criteria above, and
5 with shorter episodes in the same month discounted) (see **Figure 2**). Sensitivity analysis did not reveal
6 any bias introduced by removing these episodes. Overall, 93.2% of the non-persistent episodes were
7 associated with a lab result, of which 96.6% were collected within two days of the onset of the episode.
8
9

10
11 The symptoms considered in the analysis are reported in **Table 1**. The number of episodes associated
12 with each symptom is shown in **Figure 3**. Most symptoms (all except anorexia and dysentery), were
13 most common among the youngest children (≤ 2 years) and decreased in prevalence with age.
14

15
16 Correlations between the reporting of these symptoms during an episode ranged 0.02 to 0.64. The
17 strongest correlations were between maternal report of blood and lab-reported blood ($\rho=0.64$),
18 followed by nausea and vomiting ($\rho=0.64$), total depositions and liquid depositions ≥ 4 ($\rho=0.59$),
19 maternal report of blood and maternal report of mucus ($\rho=0.59$), malaise and stomach pain
20 ($\rho=0.55$), and malaise and anorexia ($\rho=0.43$). The correlations between the symptoms as
21 categorized in the final severity score are reported below (**Table 2**).
22
23

24 *Effects of Specific Symptoms on short-term Weight Gain*

25

26
27 Anorexia, fever, malaise, vomiting and the maximum number of stools per 24/hour period, were all
28 associated with poorer weight gain in months associated with diarrhea ($p \leq 0.010$). These symptoms
29 were associated with between 9.9 and 28.0 grams less weight gain per each day in the episode during
30 which they occurred (**Table 1**).
31

32
33 The number of days in an episode with ≥ 2 , ≥ 4 , ≥ 6 , and ≥ 8 liquid and or/semi-liquid stools were
34 strongly correlated with each other. Of these, the number of days with ≥ 4 liquid stools led to the
35 greatest improvement in model fit and was therefore retained for further analysis. Each day in which
36 ≥ 4 liquid stools were present was associated with 23.5 grams less weight gain (**Table 1**).
37
38

39 *Formation of a Severity Score*

40

41
42 In total, six factors associated with poorer weight gain. With the exception of malaise, these variables
43 were then categorized into 4 levels according to the duration of the symptom (**Table 3**), and the severity
44 score was built by summing these five categorical variables (**Table 3, Figure 4 and Supplemental Table**
45 **1**). In order to make the score more parsimonious, malaise was excluded while anorexia, which was
46 correlated with malaise ($\rho=0.43$), appeared in multivariate models to explain the association between
47 malaise and weight gain, and was also perceived as less subjective, was retained. Other symptoms were
48 more weakly correlated with each other ($\rho < 0.40$) (**Table 2**), and the exclusion of any one from the
49 overall score led to a decrease in model fit. A model that included the overall score also fit better than
50 one in which all variables were included individually.
51
52

53
54 Episodes were categorized empirically based on their distribution within this dataset as mild (score= 0,
55 no additional symptoms present beyond meeting the minimum criteria for diarrhea), moderate (1-6
56 (35th-95th percentile) and severe (≥ 7) ($>95^{\text{th}}$ percentile). Using this categorization process, episodes of
57
58
59
60

1
2
3 moderate severity were did not predict less weight gain over one month than episodes of mild severity
4 (-25.4g, $p=0.186$), and episodes of high severity predicted 132.2 g less weight gain (**Table 4**). When
5 change in WHZ was used as outcome, moderate and severe episodes predicted a loss of 0.008 ($p=0.720$)
6 and 0.171 ($p<0.001$) Z-scores over the month of the episode, respectively (**Table 4**).
7
8

9 10 *Effects of Specific Symptoms and Overall Severity on Linear Growth*

11 Of all the symptoms tested, only dysentery, as defined by laboratory-observed blood in stool, was
12 independently predictive of poorer linear growth (results not shown). Because dysentery was not
13 included in the severity score, it was then added as an independent variable to the model testing the
14 impact of the severity score overall.
15
16

17 Incident episodes of low severity were not associated with poorer linear growth or changes in HAZ,
18 while each episode of moderate severity predicted 0.035cm less linear growth and 0.009 less in HAZ.
19 Episodes of the highest severity were also unassociated with changes in linear growth and HAZ over the
20 9 month period (**Table 5**).
21
22
23
24
25

26 **Discussion**

27
28 During diarrheal episodes, anorexia/malaise, fever, vomiting, the number of days with ≥ 4 liquid stools,
29 and the maximum number of depositions per 24/hour period, were the symptoms most strongly
30 associated with poorer weight gain. This suggests the prioritization of these symptoms in the formation
31 of a severity score to characterize mild-to-moderate diarrhea in community-based study settings.
32
33

34 Several symptoms of potential interest were not collected and therefore could not be included in our
35 analysis, limiting our ability to compare our severity score to that of the 20-point Ruuska and Vesikari
36 score (11), the 24-point instrument proposed by Clark (9), or the index proposed by Ericsson and
37 subsequently adapted by Jacobs et al (25–27). The symptoms that were not collected are those which
38 require measurement or assessment of the child by a trained health worker, i.e. rectal temperature and
39 dehydration. Additionally, the maximum number of emeses in a 24-hour period was not noted. Our final
40 severity score, which is based exclusively on information extracted from the verbal report of a caregiver
41 during three-times weekly visits, is similar to the Vesakari and Clark scores, with the addition of anorexia
42 and the number of days with four or more liquid stools, and minus those components that depend on
43 trained observation, on the level of healthcare received (outpatient, hospitalization, etc.), or on
44 treatment decisions made by a health care professional during the episode (e.g. intravenous rehydration
45 therapy required yes/no) (Supplemental Table 1).
46
47
48
49
50

51 For these reasons, our score may have greater utility than existing severity indices in a variety of
52 community-based study designs where daily clinical assessments are not realistic. However, an ability to
53 compare our score to observations made in a clinical setting would be of methodological value (28),
54 particularly as symptoms based on maternal report are relatively subjective (although more severe
55 symptoms do tend to be more reliably reported (29)). A severity score that includes clinical observations
56
57
58
59
60

1
2
3 but could also be harmonized with a simplified version based on caregiver reported symptoms, and/or
4 objective measures that can be used in a community-based setting, is also desirable. The association
5 between severity and the risk of hospitalization should also be considered and assessed in a variety of
6 settings (30,31), but because hospitalization and treatment are dependent upon access and not purely
7 clinical need, these are better considered as outcomes that may be associated with diarrheal severity
8 rather than components of diarrheal severity in and of themselves.
9

10
11
12 Another weakness of our study was a relatively large number of “mild” episodes with a severity score of
13 0, and the relatively small number of “severe” episodes with a severity score of 7 or above. Many
14 episodes were of one or two days in duration, associated with a low (3 or 4) number of maximum stools
15 per 24 hour period, and, although they met epidemiological criteria for diarrhea, no others symptoms
16 that might suggest systemic involvement were present. In contrast, episodes required the presence of at
17 least three symptoms to be scored as ‘severe’ (defined here as approximately the 95th percentile). These
18 observations are consistent with the best available estimates of the proportion of categorization in mild,
19 moderate, and severe episodes in the community setting (7). In the “severe” category, there was a
20 trend towards episodes of higher scores being associated with greater weight loss, i.e. an episode of
21 severity score 15 had a greater impact than one of severity 8 (result not shown). However, because the
22 number of episodes of greater severity was small, they were grouped in a single category. The estimated
23 association between severe episodes and weight gain and linear growth is also correspondingly less
24 precise. While other categorizations of each symptom within the overall score were considered,
25 including categorizations that resulted in a greater proportion of episodes having higher scores, these
26 were less strongly associated with weight gain than the one we present here.
27
28

29
30
31
32
33 In this index, we assess duration of symptoms differently than previous scores. Both the Vesikari and
34 Clark indexes include the possibility of less than three maximum number of stools/day, which conflicts
35 with the widely accepted definition of diarrhea in a community-based setting as requiring a minimum of
36 three liquid or semi-liquid stools (**Supplemental Table 2**). We defined the bounds of an episode
37 according to the standard epidemiological definition, and then calculated the duration of each symptom
38 under that assumption. Instead of episode duration being included as a separate component, it was only
39 included indirectly, through the duration of days in which each symptom was present. We believe this is
40 important in evaluating enteric disease caused by a range of both invasive and non-invasive pathogens
41 where the illness syndrome is diverse. In contrast, previous severity scores have been built around the
42 ability of a symptom to discriminate between pathogens: for instance, rotavirus diarrhea is typically
43 associated with significant vomiting and frequent stools, but relatively less fever, and the Vesakari index
44 gives purging frequency and duration a high weight accordingly¹. Unfortunately, although common
45 bacterial enteropathogens (ETEC, *Shigella*, and *Campylobacter*) were screened for in this study (21,32),
46 rotavirus was not, and so, while validation of this scoring system against the Vesikari score would be of
47 particular interest, we are unable to do so in this study.
48
49
50
51
52

53
54 We also included in our score the total number of days with four or more liquid stools. The number of
55 total liquid + semi-liquid stools, and the number of days with ≥ 4 liquid+semi-liquid stools were strongly
56

57
58 ¹ With a maximum of 6 points related to vomiting and a maximum of 3 related to fever.
59
60

1
2
3 correlated with the maximum number of stools/24 hour period, while the number of days with ≥ 4
4 liquid stools was relatively less correlated with the total or maximum number of stools and was strongly
5 associated with poorer weight gain even after adjusting for total stools.
6
7

8 Dysentery, as defined by caregiver-reported or laboratory technician reported visible blood, was not
9 found to be a predictor of immediate episode-associated weight loss. However, it was independently
10 predictive of poorer linear growth, a finding in agreement with other reports (33). The prevention of
11 dysenteric diarrhea, which is associated with progression to persistent diarrheal (23) and mortality (34)
12 and merits prioritization. The importance of dysentery as a cause of linear growth faltering but not acute
13 weight loss also suggests that multiple measurement tools for diarrheal severity may be useful. In
14 addition to acute weight loss and linear growth, which we used here, factors such the likelihood of
15 further infectious disease, the risk of acute dehydration (8), and the risk of mortality are important child
16 health outcomes that should be considered in score-building (**Figure 1**).
17
18
19

20
21 Standardized and carefully considered measures of diarrheal severity are desirable in clinical trials,
22 intervention studies and descriptive community-based studies of diarrhea in the low-income settings
23 (35), and would improve understanding of the impact of disease control measures on morbidity burden.
24 The severity score we derived here is composed of simple components and allows for the meaningful
25 classification of a diarrheal disease episode based upon the most common adverse events associated
26 with diarrhea; depressed weight gain and poorer linear growth, an improvement over earlier scores
27 built empirically around symptom frequency. The collection of the input data for this score is highly
28 feasible and are likely available in many extant datasets; further validation could improve the estimates
29 of diarrheal severity and disease burden across epidemiologic settings.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Acknowledgements

We would like to thank Dr. William Pan for his contribution to the data analysis and Dr. Jamie Perin for her review of the manuscript. We would also like to thank Matilda Bustos Aricara, Victoria Lopez Manuyama, Marla Judith Aricari Huanari, and Lleny Amasifuen Llerena, for their hard work and thoughtful contributions in the field, and the study families for their generosity with their time and willingness to participate.

Funding

This work was supported by the National Institutes of Health [K01-TW05717 to M.K]. G.L. was supported by a National Institutes of Health International Maternal and Child Health Training Grant [T32HD046405] (PI Dr. Joanne Katz) and a Proctor and Gamble Doctoral Dissertation Fellowship, awarded by the Johns Hopkins Bloomberg School of Public Health. The funders had no role in the collection, analysis, or interpretation of the data.

Contributors

MK conceived and designed the study. MK, MPO, PPY designed the data collection tools, monitored recruitment and data collection for the study, and supervised the study. PPY managed and cleaned the data. GL designed and implemented the analysis, CFW, LEC, REB, and DAS provided guidance during the analysis, and contributed to the interpretation of data. All authors helped write and critically review the article, and all authors have approved the final version to be published and agree to be accountable for all aspects of the work. MK and GL are the guarantors.

Competing Interests

We have read and understood the BMJ policy on declaration of interests and declare the following interests: None. All authors have completed the ICMJE uniform disclosure form at www.icjme.org/coi_disclosure.pdf (available on request from the corresponding author).

Data sharing

Raw data used in the analysis is available on request from the corresponding author at mkosek@jhsph.edu. Statistical code is also available upon request.

Ethical Approval

This study was approved by the Institutional Review boards of the Johns Hopkins Bloomberg School of Public Health, Baltimore, MD (IRB H.22.01.01.02.A), the US Naval Medical Research Center, Silver Springs, MD (IRB NMRCD.2002.0009), and Asociación Benéfica PRISMA, Lima, Peru (no IRB number). All participating families gave signed, informed consent before taking part in the study.

Declaration of Transparency

Gwenyth Lee confirms that this article is an honest, accurate and transparent account of the study reported, that no important aspects of the study have been omitted; and that any discrepancies from the study as planned have been explained.

References

1. Guerrant RL, Kosek M, Moore S, et al. Magnitude and Impact of Diarrheal Diseases. *Arch Med Res.* 2002;33(4):351–5.
2. Liu L, Johnson HL, Cousens S et al. Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000. *Lancet.* 2012;379(9832):2151–61.
3. Fischer-Walker CL, Perin J, Aryee MJ, et al. Diarrhea incidence in low- and middle-income countries in 1990 and 2010: a systematic review. *BMC Public Health.* 2012;12(1):220.
4. Johnston BC, Shamseer L, da Costa BR, et al. Measurement issues in trials of pediatric acute diarrheal diseases: a systematic review. *Pediatrics.* 2010;126(1):e222–31.
5. Baqui AH, Black RE, Yunus M, et al. Methodological issues in diarrhoeal diseases epidemiology: definition of diarrhoeal episodes. *Int J Epidemiol.* 1991;20(4):1057–63.
6. Stanton B, Clemens JD. Chronic diarrhoea: a methodologic basis for its apparent heterogeneity. *Trop Geogr Med.* 1989;41(2):100–7.
7. Lamberti LM, Fischer-Walker CL, Black RE. Systematic review of diarrhea duration and severity in children and adults in low- and middle-income countries. *BMC Public Health.* 2012;12(1):276.
8. Black RE, Merson M, Huq I, et al. Incidence and Severity of Rotavirus and Escherichia Coli Diarrhoea: Implications for Vaccine Development. *Lancet.* 1981;1978–80.
9. Clark HF, Borian FE, Bell LM, et al. Protective effect of WC3 vaccine against rotavirus diarrhea in infants during a predominantly serotype 1 rotavirus season. *Vaccine.* 2012;158(3):570–87.
10. Flores J, Perez-schael I, Gonzales M, et al. Protection against severe rotavirus diarrhoea by rhesus rotavirus vaccine in Venezuelan infants. *Lancet.* 1986;329(8538):882–4.
11. Ruuska T, Vesikari T. Rotavirus disease in Finnish children: use of numerical scores for clinical severity of diarrhoeal episodes. *Scan J Infect Dis.* 1990;22(3):259–67.

12. Schmidt W-P, Arnold BF, Boisson S, et al. Epidemiological methods in diarrhoea studies — an update. *Int J Epidemiol*. 2011;40(6):1678–92.
13. Freedman SB, Eltorky M, Gorelick M. Evaluation of a gastroenteritis severity score for use in outpatient settings. *Pediatrics*. 2010;125(6):e1278–85.
14. Mertz HR, Beck C, Dixon W, et al. Validation of a new measure of diarrhea. *Dig Dis Sci*. 1995;40(9):1873–82.
15. Black RE, Allen LH, Bhutta ZA, et al. Maternal and child undernutrition: global and regional exposures and health consequences. *Lancet*. 2008;371(9608):243–60.
16. Yoon P, RE B, Moulton H, et al. The effect of malnutrition on the risk of diarrheal and respiratory mortality in children < 2 y of age in Cebu, Philippines. *Am J Clin Nutr*. 1997;65(4):1070–7.
17. Guerrant RL, Schorling JB, McAuliffe JF, et al. Diarrhea as a cause and an effect of malnutrition: diarrhea prevents catch-up growth and malnutrition increases diarrhea frequency and duration. *Am J Trop Med Hyg*. 1992;47(1):28–35.
18. Richard SA, Black RE, Gilman RH, et al. Wasting is associated with stunting in early childhood. *J Nutr*. 2012;142(7):1291–6.
19. Grantham-McGregor S. A review of studies of the effect of severe malnutrition on mental development. *J Nutr*. 1995;125(8):2233.
20. Haas JD, Murdoch S, Rivera J, et al. Early nutrition and later physical work capacity. *Nutr Rev*. 1996;54(2):S41.
21. Kosek M, Peñataro Yori P, Pan WK, et al. Epidemiology of highly endemic multiply antibiotic-resistant shigellosis in children in the Peruvian Amazon. *Pediatrics*. 2008;122(3):e541–9.
22. Lee G, Peñataro Yori P, Paredes Olortegui M et al. Comparative effects of vivax malaria, fever and diarrhoea on child growth. *Int J Epidemiol*. 2012;41(2):531–9.
23. Baqui AH, Black RE, Sack RB, et al. Epidemiological and clinical characteristics of acute and persistent diarrhoea in rural Bangladeshi children. *Acta Paediatr Suppl*. 1992;81(s383):15–21.
24. Stolwijk A, Straatman H, Zielhuis G. Studying seasonality by using sine and cosine functions in regression analysis. *J Epidemiol Commun H*. 1999;53(4):235–8.
25. Ericsson C, DuPont H, Sullivan P, et al. Bicozamycin, A poorly absorbable antibiotic, effectively treats travelers diarrhea. *Ann Intern Med*. 1983;98(1):20.
26. Ericsson C, Johnson P, Dupont H, et al. Ciprofloxacin or Trimethoprim-Sulfamethoxazole as Initial Therapy for Travelers' Diarrhea: A Placebo-Controlled, Randomized Trial. *Ann Intern Med*. 1987;106:216–20.

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
27. Jacobs J, Gloyd S, Margarita Jimenez L, et al. Treatment of Acute Childhood Diarrhea With Homeopathic Medicine: A Randomized Clinical Trial in Nicaragua. *Pediatrics*. 1994;93:719.
28. Givon-Lavi N, Greenberg D, Dagan R. Comparison between two severity scoring scales commonly used in the evaluation of rotavirus gastroenteritis in children. *Vaccine*. 2008;26(46):5798–801.
29. Lee G, Cama V, Gilman RH et al. Comparison of two types of epidemiological surveys aimed at collecting daily clinical symptoms in community-based longitudinal studies. *Ann Epidemiol*. 2010;20(2):151–8.
30. Seidlein L Von, Kim DR, Ali M, et al. A multicentre study of Shigella diarrhoea in six Asian countries: disease burden, clinical manifestations, and microbiology. *PLoS Med*. 2006;3(9):1556–69.
31. Fischer-Walker CL, Sack D, Black RE. Etiology of diarrhea in older children, adolescents and adults: a systematic review. *PLoS Negl Trop Dis*. 2010;4(8):e768.
32. Lee G, Paredes Olortegui M, Yori PP, et al. Effects of Shigella, Campylobacter, and ETEC-associated Diarrhea on Childhood Growth. *Ped Infect Dis J*. 2014; epub ahead of print.
33. Alam DS, Marks GC, Baqui AH, et al. Association between clinical type of diarrhoea and growth of children under 5 years in rural Bangladesh. *Int J Epidemiol*. 2000;29(5):916–21.
34. Victora CG, Huttly SRA, Fuchs SC, et al. International differences in clinical patterns of diarrhoeal deaths: a comparison of children from Brazil, Senegal, Bangladesh, and India. *J Diarrhoeal Dis Res*. 1993;11(1):25–9.
35. Sinha IP, Altman DG, Beresford MW, et al. Standard 5: selection, measurement, and reporting of outcomes in clinical trials in children. *Pediatrics*. 2012;129(S3):S146–S152.

Tables and Figures

Table 1: Association of Symptoms with Weight Gain

Caption: In the below model, age (as fractional polynomials, term1= $age^{-2} - 1.16$ and term2= $\ln(age) * age^{-2} - 0.08$), season (with sine/cosine terms), and an AR(1) covariance structure.

	Present in episode yes/no	duration
	change in weight (g) associated with symptom presence	change in weight (g) per days present
Anorexia	-46.6 (-87.7, -5.6) (p=0.026)	-12.9 (-23.1, -2.7) (p=0.013)
Blood in Stool (observed by Mother)	-2.1 (-61.7, 57.5) (p=0.946)	-4.1 (-30.1, 21.9) (p=0.757)
Blood in Stool (observed by lab tech)	10.3 (-72.8, 93.5) (p=0.807)	N/A
Fever	-47.9 (-89.1, -6.5) (p=0.023)	-19.5 (-36.7, -2.3) (p=0.026)
Nausea	-1.5 (-60.8, 57.9) (p=0.962)	-2.2 (-29.6, 25.2) (p=0.875)
Malaise	-49.5 (-85.0, -14.1) (p=0.006)	-9.9 (-18.3, -0.4) (p=0.022)
Mucus in Stool (observed by Mother)	-4.5 (-47.3, 38.3) (p=0.837)	-0.1 (-15.0, 15.0) (p=0.998)
Mucus in Stool (observed by Lab tech)	2.9 (-34.8, 40.6) (p=0.879)	N/A
Stomach Pain	-13.9 (-48.9, 21.0) (p=0.435)	-5.8 (-13.7, 2.2) (p=0.156)
Vomiting	-57.0 (-109.3, -4.7) (p=0.033)	-28.0 (-52.9, 30.8) (p=0.028)
Four or more liquid stools in a 24/hr period	-43.1 (-79.6, -6.6) (p=0.021)	-23.5 (-37.5, -9.5) (p=0.001)
Maximum number of stools /24 hr period (continuous)	-9.9 (-18.0, -1.8) (p=0.016)	N/A
Episode Duration (per day - continuous)	-5.1 (-12.5, 2.4) (p=0.181)	N/A

Table 2: Correlations between symptoms retained in final severity score (N=3,915)

Symptoms are categorized here according to the manner that they are included in the final score (0 days with symptom = 0, 1-2 days with symptom=1, 3-4 days with symptom=2, 5+ days with symptom=3).

	Anorexia	Fever	Vomiting	Liquid Stools	Max Stools
Days with Anorexia	1				
Days with Fever	0.24	1			
Days with Vomiting	0.23	0.30	1		
Days with ≥ 4 Liquid Stools	0.24	0.27	0.29	1	
Maximum stools/24hr period	0.32	0.29	0.30	0.38	1

Table 3: Severity Scorecard

Symptom	Category	Points
Diarrhea	>=3 liquid or semi-liquid stools per day, for 1-13 days, with gaps of no more than two days	
Fever	No Fever	+0
	Fever for 1-2 days	+1
	Fever for 3-4 days	+2
	Fever for 5+ days	+3
Anorexia	No Anorexia	+0
	Anorexia for 1-2 days	+1
	Anorexia for 3-4 days	+2
	Anorexia for 5+ days	+3
Vomiting	No Vomiting	+0
	Vomiting for 1-2 days	+1
	Vomiting for 3-4 days	+2
	Vomiting for 5+ days	+3
Liquid Stools	No days with >=4 liquid stools	+0
	1-2 days with >=4 liquid stools	+1
	3-4 days with >=4 liquid stools	+2
	5+ days with >=4 liquid stools	+3
Maximum number of stools in a 24 hour period during the episode	3	+0
	4-5	+1
	6-7	+2
	>=8	+3
TOTAL		0-15

Table 4: Association between Severity Score and change in Weight and Weight-for-Height

The association between incident episodes of diarrheal classified as low (score 0), medium severity (score 1-6) and high severity (score ≥ 7) on the change in weight and weight-for-height Z over 1-month intervals, is shown below. Age (same fractional polynomials as in symptom-specific models) and season (sine and cosine terms) were also adjusted for (beta coefficients not shown).

	1-month change in Weight (g)	1month change in WHZ (Z-score)
Low Severity	ref	ref
Medium Severity	-25.4 (-63.0, 12.2) (p=0.186)	-0.008 (-0.052, 0.036) (p=0.720)
High Severity	-132.2 (-213.6, -50.7) (p=0.001)	-0.171 (-0.266, -0.077) (p<0.001)

Table 5: Association between Severity Score and Linear Growth

The association between incident episodes of diarrheal classified as low (score 0), medium severity (score 1-6) and high severity (score ≥ 7) on the change in height and HAZ over 9-month intervals, is shown below. Age (fractional polynomials used to adjust for age in the height model are term1= $age^{-2} - 0.56$ and term3= $\ln(age) * age^3 - 2.41$), season (sine and cosine terms), stunting, and WHZ (categorized as >0 , 0 to -1, and <-1) were also adjusted for (beta coefficients not shown). In the HAZ model, fractional polynomials for age are $age^{-2} - 1.80$ and $\ln(age) * age^2 - 0.53$.

	9mo change in Ht (cm)	9mo change in HAZ (Z-score)
Low-severity episodes (incidence)	-0.014 (-0.042, 0.015) (p=0.348)	-0.001 (-0.012, 0.009) (p=0.755)
Medium-severity episodes	-0.035 (-0.056, -0.014) (p=0.001)	-0.009 (-0.016, -0.001) (p=0.025)
High-severity episodes	-0.011 (-0.067, 0.044) (p=0.690)	-0.008 (-0.028, 0.012) (p=0.439)
Episodes of dysentery	-0.112 (-0.189, -0.036) (p=0.004)	-0.033 (-0.061, -0.006) (p=0.018)

1
2
3 **Figure 1: Conceptual Diagram of Idealized Severity Score**
4

5 **Figure 2: Episodes included in the analysis**
6

7 **Figure 3: Distribution of Symptoms:** Out of all episodes (n=3,915)
8

9 **Figure 4: Histogram of severity score distribution:** The y-axis (frequency) indicates the number of
10 episodes assigned to the score (N= 3,915).
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Title: An Instrument for the Assessment of Diarrheal Severity ~~in~~based on a Longitudinal Community-Based ~~Studies~~Study

Authors: Gwennyth Lee, Pablo Peñataro_Yori, Maribel Paredes_Olortegui, Laura E. Caulfield, David A. Sack, Christa Fischer-Walker, ~~Bob~~Robert E. Black, Margaret Kosek*

Department of International Health, Johns Hopkins School of Public Health, Baltimore, MD 21205, USA, Asociación Benéfica Proyectos de Informática, Salud, Medicina, y Agricultura (A.B. PRISMA), Ramirez Hurtado 622, Iquitos, Peru.

Correspondence to:

~~*~~* e-mail: mkosek@jhsp.edu

Assistant Professor
Johns Hopkins Bloomberg School of Public Health
615 N. Wolfe St E5545
Baltimore, MD21205
(410)-955-5932

Field Code Changed

1
2
3
4
5
6
7
8
9 **Abstract World Count:** [292296](#)

10 **Draft World Count:** [3,4314,083](#)

11
12
13
14 **Abstract:**

15
16 **Objective** Diarrhea is a significant contributor to morbidity and is among the leading causes of death of
17 children living in poverty. As such, the incidence, duration, and severity of diarrheal episodes in the
18 household are often key variables of interest in a variety of community-based studies. However, there
19 currently exists no means of defining diarrheal severity that are: (a) specifically designed and adapted
20 for community-based studies; (b) associated with poorer child outcomes; and (c) agreed upon by the
21 majority of researchers. Clinical severity scores do exist and are used in health care settings, but these
22 tend to focus on relatively [moderate to](#) severe dehydrating and dysenteric disease, require trained
23 observation of the child, and, given the variability of access and utilization of health care, fail to
24 sufficiently describe the spectrum of disease in the community setting.

25
26 **Design** Longitudinal cohort study

27
28 **Setting** Santa Clara de Nanay, a rural community in the Northern Peruvian Amazon

29
30 **Participants** 442 infants and children 0-72 months of age

31
32 **Main Outcome Measures** Change in weight over one month intervals and change in length/height over
33 9-month intervals

34
35 **Results** Diarrheal episodes with symptoms of fever, anorexia, vomiting, greater numbers of liquid stools
36 per day, and greater number of total stools per day, were associated with poorer weight gain compared
37 to episodes without these symptoms. An instrument to measure severity was constructed based upon
38 the duration of these symptoms over the course of a diarrheal episode.

39
40 **Conclusions** In order to address limitations of existing diarrheal severity scores in the context of
41 community-based studies, we propose an instrument comprised of diarrhea-associated symptoms easily
42 measured by community health workers and based on the association of these symptoms with poorer
43 child growth. This instrument can be used to test the impact of interventions on [the burden of](#) diarrheal
44 disease ~~severity~~.

45
46
47 **Strengths and Limitations of the Study:**

48
49 -Intensive (three-times weekly) surveillance was used to capture symptoms of diarrheal severity in a
50 community-based context, and to relate these to weight gain.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

~~Symptoms~~ A lack of information about clinical signs associated with severe disease, including dehydration and rectal temperature, limit the comparability of this instrument to existing diarrheal severity scores.

Introduction

~~Diarrhea is common cause of morbidity and mortality among children in the developing world (1). In addition to causing an estimated 0.75 million deaths per year (2), is estimated that the average child under five in the developing world will experience 2.9 episodes per year (3). The severity of these episodes is a common factor of interest in community-based epidemiological studies designed to test the impact of an intervention and/or quantify the burden of diarrheal disease (4).~~

~~Within the context of community-based studies diarrhoea is defined as three or more loose stools per 24-hour period (5), prolonged diarrhoea is diarrhoea lasting between 7-13 days, and 'persistent' diarrhoea as an episode of at least 14 days (6,7). These definitions were standardized in the early 1990s, leading to greater comparability between studies, and progress in the field.~~

~~Diarrhea is common cause of morbidity and mortality among children in the developing world (1). In addition to causing an estimated 0.75 million deaths per year (2), is estimated that the average child under five in the developing world will experience 2.9 episodes per year (3). The severity of these episodes is a common factor of interest in community-based epidemiological studies designed to test the impact of an intervention and/or quantify the burden of diarrheal disease (4).~~

~~Within the context of community-based studies diarrhoea is defined as three or more loose stools per 24-hour period (5), prolonged diarrhoea is diarrhoea lasting between 7-13 days, and 'persistent' diarrhoea as an episode of at least 14 days (6,7). These definitions were standardized in the early 1990s, leading to greater comparability between studies, and progress in the field.~~

Definitions of diarrheal severity, however, have remained variable (4). ~~Clinical indicators of severity such as dehydration and dysentery (8)(4). Clinical indicators of severity such as dehydration and dysentery (8)~~ are associated with an acute risk of patient mortality and are used to guide therapy. These symptoms, in addition to need for hospitalization can define moderate to severe diarrhoea among cases presenting for care at a healthcare center, but will not gradate between the majority of mild to moderate cases in the community (see **Figure 1**). As diarrhoea case fatality rates decline, there is increasing interest in understanding the impact of mild-to-moderate disease on child health and development. For these episodes, there is a need for non-clinical measurement instruments adapted for use at a community level.

~~Several severity measurement instruments have been developed for classifying rotavirus diarrhoea (9-11). However, these scores were not designed to differentiate severity of non-rotavirus diarrhoea, which is less frequently associated with symptoms such as vomiting. Although rotavirus is the most frequently isolated pathogen among hospitalized diarrhoea cases, there are other pathogens that are isolated more frequently in a typical community context. Furthermore, instruments that include hospitalization as a~~

1
2
3
4
5
6
7
8
9 model input are problematic in settings where access to inpatient care facilities is heterogeneous, as can
10 be observed in many low and middle-income settings.

11 Previous instruments included components such as rectal temperature and indexes of dehydration
12 require either an invasive measurement or one that may be challenging to consistently measure across
13 studies. These scales cannot be implemented in the context of community-based studies, where
14 caregivers may not seek care for episodes of mild to moderate diarrhea and where surveillance is
15 frequently bi-weekly or even weekly (12) and many episodes resolve in the interval between a study
16 worker's regularly scheduled visits. While some studies have attempted to correct this problem through
17 the creation of "modified" Vesikari scores (13,14), these scores were based on data from Canadian
18 infants and HIV+ infants, respectively, making their findings less generalizable to the typical cases of
19 pediatric diarrhea in the developing world.

20
21
22 Several severity measurement instruments have been developed for classifying rotavirus diarrhea (9–
23 11). However, these scores were not designed to differentiate severity of non-rotavirus diarrhea, which
24 is less frequently associated with symptoms such as vomiting. Although rotavirus is the most frequently
25 isolated pathogen among hospitalized diarrhea cases, there are other pathogens that are isolated more
26 frequently in a typical community context. Furthermore, instruments that include hospitalization as a
27 model input are problematic in settings where access to inpatient care facilities is heterogeneous, as can
28 be observed in many low and middle-income settings.

29
30 Previous instruments have included components such as rectal temperature and indexes of dehydration
31 require either an invasive measurement or one that may be challenging to consistently measure across
32 studies. These scales cannot be implemented in the context of community-based studies, where
33 caregivers may not seek care for episodes of mild-to-moderate diarrhea and where surveillance is
34 frequently bi-weekly or weekly (12) and many episodes resolve in the interval between a study worker's
35 regularly scheduled visits. While some studies have attempted to correct this problem through the
36 creation of "modified" Vesikari scores (13,14), these scores were based on data from Canadian infants
37 and HIV+ infants, respectively, making their findings less generalizable to the typical cases of pediatric
38 diarrhea in the developing world.

39
40 Finally, the determination of severity in the formation of these instruments has generally been based on
41 the empiric distribution of characteristics such as fever or dysentery associated with that particular
42 cohort, rather than through association with morbidity (4)-(4). There are currently no instruments that
43 correlate on the high end to severe outcomes such as mortality and hospitalization, and on the middle-
44 to-low end with other, more frequently occurring adverse health outcomes.

45
46 Acute weight loss associated with a diarrheal episode puts a child at risk of becoming underweight
47 and/or wasted, outcomes associated with an increased risk of mortality (15,16), further infectious
48 disease (17) and future stunting (18). Poorer linear growth in early childhood is associated with long-
49 term negative outcomes including poorer cognitive development (19), adult work capacity and income
50 (20), and, for girls, poorer maternal health (15). Therefore, short-term weight gain and medium-to-long
51 term linear growth are appropriate functional outcomes through which to validate measures of disease
52

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

severity, and symptoms associated with poorer growth should be prioritized in the formation of diarrheal severity scores.

Using data from a previously established longitudinal cohort with a high incidence of diarrhea and stunting and with standard community-based active surveillance measures, we evaluated the impact of diarrheal-associated symptoms on short-term weight gain in the subsequent temporal period. From this, we formed a diarrheal severity score to predict acute weight loss as well as depressed linear growth over longer temporal windows. This instrument may be validated for use in community based studies, clinical trials, and water, sanitation, and hygiene interventions.

Methods

Data were from a prospective, community-based study of 442 children 0-72 months of age living in the community of Santa Clara, located 15 km southeast of Iquitos, Peru. The cohort and study design were described previously (21,22); the overall objective was to explore the association between common etiologies of diarrhea and early childhood growth. The work described here was a prespecified secondary objective of the study.

From October 2002 – April 2006, participating families were visited three times weekly by a trained health promoter to document the number and consistency of stools passed by the child over the previous 24-hour period, as well as other symptoms such as fever, anorexia, malaise, nausea, vomiting, stomach pain, and the reported presence of blood and mucus in the child's feces. Acute weight loss associated with a diarrheal episode puts a child at risk of becoming underweight and/or wasted, outcomes associated with an increased risk of mortality (15,16), further infectious disease (17) and future stunting (18). Poorer linear growth in early childhood is associated with long-term negative outcomes including poorer cognitive development (19), adult work capacity and income (20), and, for girls, poorer maternal health (15). Therefore, short-term weight gain and medium-to-long term linear growth are appropriate functional outcomes through which to validate measures of disease severity, and symptoms associated with poorer growth should be prioritized in the formation of diarrheal severity scores.

Using data from a previously established longitudinal cohort with a high incidence of diarrhea and stunting and with standard community-based active surveillance measures, we evaluated the impact of diarrheal-associated symptoms on short-term weight gain in the subsequent temporal period. From this, we formed a diarrheal severity score to predict acute weight loss as well as depressed linear growth over longer temporal windows. This instrument may be validated for use in community based studies, clinical trials, and water, sanitation, and hygiene interventions.

Methods

1
2
3
4
5
6
7
8
9 Data were from a prospective, community-based study of 442 children 0-72 months of age living in the
10 community of Santa Clara, located 15 km southeast of Iquitos, Peru. The cohort and study design were
11 described previously (21,22); the overall objective was to explore the association between common
12 etiologies of diarrhea and early childhood growth. The work described here was a prespecified
13 secondary objective of the study.

14
15 From October 2002 – April 2006, participating families were visited three-times weekly by a trained
16 health promoter to document the number and consistency of stools passed by the child over the
17 previous 24-hour period, as well as other symptoms such as fever, anorexia, malaise, nausea, vomiting,
18 stomach pain, and the reported presence of blood and mucus in the child's feces. For example, malaise
19 was translated as "malestar general" and described to mothers as a lack of energy or irritability in the
20 child, and anorexia (translated as "recibe bien la comida") was described as the child's
21 willingness/eagerness to eat as usual. This generated a continuous history of diarrheal disease over the
22 surveillance period for each participating child (see **Figure 2**). Anthropometry was collected monthly,
23 and socioeconomic and demographic information were collected during two community censuses
24 before and during the study period. Diarrhea was defined by three or more semi-liquid stools reported
25 over a 24-hour period, with episodes separated by at least three symptom-free days. Stool samples
26 were collected as soon as possible after the case definition for diarrhea was met, and not more than two
27 days after the episode ended. Fecal blood and fecal mucus, as reported by a lab technician, were also
28 reported once per episode.

29
30 Symptoms associated with diarrhea were defined as having occurred during the diarrheal episode, if
31 they were present on any day of the episode. The duration of symptoms associated with diarrhea was
32 defined as the number of days of the episode upon which the symptom occurred. Symptoms which
33 were present the day before or the day after an episode of diarrhea were not counted.

34
35 Since persistent diarrhea is regarded as a separate epidemiological phenomenon with effects on growth
36 apart from those of shorter episodes (23), (23), only episodes of <14 days were retained in the analysis.
37 In this cohort less than two percent of episodes were persistent (≥ 14 days = 1.52.4% of all episodes).

38 39 40 41 **Statistical Methods**

42 The percentages of episodes associated with a given symptom by age were tabulated and compared
43 (ANOVA), and correlations and partial correlations between the presence of symptoms during an
44 episode, and the duration of symptoms during an episode were calculated. All analysis was performed
45 using Stata 11 & Stata 12 (Statacorp, College Station, TX, USA).

46 47 *Effects of Specific Symptoms on short-term Weight Gain*

48
49 The effect of the presence of a symptom (see list of symptoms in **Table 1**) on a child's weight gain was
50 modeled using change in weight of the child before versus after the episode. Only intervals in which a
51 diarrheal episode was present were include in the model (i.e. episodes of diarrhea were compared to
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

each other, and were not compared with periods in which no diarrhea occurred). Only episodes that occurred between two instances of anthropometry one month apart were considered, i.e., episodes which overlapped an anthropometric measurement were discounted. In order to avoid instances in which acute dehydration might have impacted weight gain, episodes that ended less than two days before anthropometry were also excluded. ~~When~~ Rather than include the same one-month interval of anthropometry repeatedly within the model, when more than one episode occurred within the same one month interval, only the episode of longer duration was retained ~~in the model~~, and the total number of episodes in the month was considered as a covariate in the analysis. Sensitivity analysis was performed to determine the effect of these omissions on model outputs.

$$Wt_{ij} - Wt_{i-1,j} = b_j + \beta_0 + \beta_1 D_{\text{symptom}} + \beta_2 \sin_{\text{season}} + \beta_3 \cos_{\text{season}} + \dots + \beta_4 \text{Age Term 1} + \beta_5 \text{Age Term 2} + \varepsilon_{ij}$$

$$Wt_{ij} - Wt_{i-1,j} = b_j + \beta_0 + \beta_1 D_{\text{symptom}} + \beta_2 \sin_{\text{season}} + \beta_3 \cos_{\text{season}} + \dots + \beta_4 \text{Age Term 1} + \beta_5 \text{Age Term 2} + \varepsilon_{ij}$$

(Equation 1).

The final model used to evaluate associations of symptoms with weight gain is shown in equation 1.

D_{symptom} represents the presence or absence of a symptom during the episode or the duration, t (in days) of the symptom during an episode (Column 2 of **Table 31**). Seasonal variation in weight gain was modeled by adding the terms $\text{sine}(\frac{2d\pi}{t})$ and $\text{cosine}(\frac{2d\pi}{t})$, where d is the day of the year, and t is 365 (24)-(24). Age Term 1 and Age Term 2 are fractional polynomials used to estimate the impact of age on monthly weight gain. The models were also fitted with a child-level random intercept and a covariance structure that fixed a first-order autoregressive residual structure to account for those instances in which a child experienced episodes of diarrhea over consecutive one-month intervals.

Formation of a Severity Score

Symptoms negatively associated with weight gain were categorized by duration and combined to form a severity score. ~~When several symptoms were strongly correlated ($\rho > 0.40$), only the symptom that improved model fit was included in the severity score. In order to judge how many points should be given to symptoms of a given duration, models where duration was categorical were used to determine whether the association per day of the symptom on weight gain was additive, or whether there were threshold effects. After forming the score, sensitivity analysis was used to check that the inclusion of each additional component improved the overall model fit.~~

~~This~~ The score was then collapsed into three categories representing relatively mild, moderate, and severe diarrhea. The same model was then fit using the categorized variable. The unadjusted mean change in weight and weight for height Z score (WHZ) by severity category, and the adjusted one-month change in WHZ by severity category, were also estimated.

Effects of Specific Symptoms and Overall Severity on Linear Growth

Field Code Changed

Field Code Changed

In order to examine the relationship between individual symptoms and change in length/height, the cumulative incidence of episodes with and without each symptom was summed over nine-month intervals, and the effect of these episodes on linear growth (change in length/height) was modeled using the equation in Equation 2, where $\frac{D_{\text{symptom_present}}}{D_{\text{symptom_present}}}$ is the cumulative incidence of diarrheal episodes in which the symptom occurred, and $\frac{D_{\text{symptom_absent}}}{D_{\text{symptom_absent}}}$ is the cumulative incidence of diarrheal episodes in which the symptom was absent, during the nine-month interval. The same seasonal terms and a set of fractional polynomial terms generated separately from those in the weight model were included. The models were also fitted with a child-level random intercept and a covariance structure that fixed a first-order autoregressive residual structure.

$$Ht_{ij} - Ht_{i-9,j} = b_j + \beta_0 + \beta_1 \frac{D_{\text{symptom_present}}}{D_{\text{symptom_present}}} + \beta_2 \frac{D_{\text{symptom_absent}}}{D_{\text{symptom_absent}}} + \beta_3 \sin_{\text{season}} + \beta_4 \cos_{\text{season}} + \beta_5 \text{AgeTerm}_1 + \beta_6 \text{AgeTerm}_2 + \varepsilon_{ij}$$

$$Ht_{ij} - Ht_{i-9,j} = b_j + \beta_0 + \beta_1 \frac{D_{\text{symptom_present}}}{D_{\text{symptom_present}}} + \beta_2 \frac{D_{\text{symptom_absent}}}{D_{\text{symptom_absent}}} + \beta_3 \sin_{\text{season}} + \beta_4 \cos_{\text{season}} + \beta_5 \text{AgeTerm}_1 + \beta_6 \text{AgeTerm}_2 + \varepsilon_{ij}$$

(Equation 2).

The impact of episodes of varying severity, as categorized by the severity score developed above, was then tested similarly, using a model with three incidence terms, $\frac{D_{\text{mild}}}{D_{\text{mild}}}$, $\frac{D_{\text{moderate}}}{D_{\text{moderate}}}$, and $\frac{D_{\text{severe}}}{D_{\text{severe}}}$, representing the cumulative incidence of mild, moderate, and severe episodes in the nine-month interval, respectively. A similar model using nine-month change in HAZ as an outcome was used to test the effects of disease severity on HAZ.

Results

A total of 3,738,915 acute episodes were available for analysis. Of these, 2,461,462 were used in building the severity score (on the basis of being associated with anthropometry according to the criteria above, and with duplicate shorter episodes in the same month discounted) (see Figure 2). Sensitivity analysis did not reveal any bias introduced by removing these episodes. Overall, 93.2% of the non-persistent episodes were associated with a lab result, of which 96.6% were collected within two days of the onset of the episode.

The symptoms considered in the analysis are reported in Table 1. The number of episodes associated with each symptom is shown in Figure 3. Most symptoms (all except anorexia and dysentery), were most common among the youngest children (<=2 years) and decreased in prevalence with age.

Correlations between the reporting of these symptoms during an episode ranged 0.01802 to 0.64364. The strongest correlations were between maternal report of blood and lab-reported blood (rho=0.64364), followed by nausea and vomiting (rho=0.64264), total depositions and liquid depositions >=4 (rho=0.58959), maternal report of blood and maternal report of mucus (rho=0.58659), malaise and

Field Code Changed

Field Code Changed

Field Code Changed

Field Code Changed

Field Code Changed

Field Code Changed

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

stomach pain ($\rho=0.55055$), and malaise and anorexia ($\rho=0.427$). All other correlations were less than 0.4-43). The correlations between the symptoms as categorized in the final severity score are reported below (Table 2).

Effects of Specific Symptoms on short-term Weight Gain

Anorexia, fever, malaise, vomiting and the maximum number of stools per 24/hour period, were all associated with poorer weight gain in months associated with diarrhea ($p<0.010$). These symptoms were associated with between 9.69 and 21.328.0 grams less weight gain per each day in the episode during which they occurred (Table 1).

The number of days in an episode with ≥ 2 , ≥ 4 , ≥ 6 , and ≥ 8 liquid and or/semi-liquid stools were strongly correlated with each other. Of these, the number of days with ≥ 4 liquid stools led to the greatest improvement in model fit and was therefore retained for further analysis. Each day in which ≥ 4 liquid stools were present was associated with 23.35 grams less weight gain (Table 1).

Formation of a Severity Score

In total, six factors were found to be predictive of associated with poorer weight gain: anorexia, malaise, vomiting, fever, the maximum number of stools per 24-hour period, and the number of days with 4 or more liquid per 24-hour period. Anorexia and malaise were strongly correlated ($\rho=0.432$), and therefore only anorexia, which had the greater improvement in weight-model fit, was retained in the final severity score. Other symptoms were more weakly correlated when categorized by duration ($\rho < 0.40$) (Table 2). These these variables were then categorized into 4 levels according to the duration of the symptom (Table 3). The, and the severity score was built by summing these five categorical variables (Table 3, Figure 4 and Supplemental Table 1). In order to make the score more parsimonious, malaise was excluded while anorexia, which was correlated with malaise ($\rho=0.43$), appeared in multivariate models to explain the association between malaise and weight gain, and Figures 2 was also perceived as less subjective, was retained. Other symptoms were more weakly correlated with each other ($\rho < 0.40$) (Table 2), and 4) the exclusion of any one from the overall score led to a decrease in model fit. A model that included the overall score also fit better than one in which all variables were included individually.

Episodes were categorized empirically based on their distribution within this dataset as mild (score= 0, no additional symptoms present beyond meeting the minimum criteria for diarrhea), moderate (1-6 (35th-95th percentile) and severe (≥ 7) (>95th percentile). Using this categorization process, episodes of moderate severity were found to predict 51.8g less weight gain over one month than episodes of mild severity (reference value (-25.4g, $p=0.186$), and episodes of high severity were found to predict 135.2g less weight gain (Table 4). When change in WHZ was used as outcome, moderate and severe episodes predicted a loss of 0.049008 ($p=0.720$) and 0.1822171 ($p<0.001$) Z-scores over the month of the episode, respectively (Table 4).

Effects of Specific Symptoms and Overall Severity on Linear Growth

Formatted: Font: Bold

Formatted: Font: Not Bold

Formatted: Font: Not Bold

Formatted: Font: Not Bold

Formatted: Font: Not Bold

1
2
3
4
5
6
7
8
9 Of all the symptoms tested, only dysentery, as defined by laboratory-observed blood in stool, was
10 independently predictive of poorer linear growth (results not shown). Because dysentery was not
11 included in the severity score, it was then added as an independent variable to the model testing the
12 impact of the severity score overall.

13
14 Incident episodes of low severity were not associated with poorer linear growth or changes in HAZ,
15 while each episode of moderate severity predicted 0.041cm035cm less linear growth and 0.04009 less
16 in HAZ. Episodes of the highest severity were also unassociated with changes in linear growth and HAZ
17 over the 9 month period (Table 5).

20 Discussion

21
22 During diarrheal episodes, anorexia/malaise, fever, vomiting, the number of days with ≥ 4 liquid stools,
23 and the maximum number of depositions per 24-hour period, were the symptoms most strongly
24 associated with poorer weight gain. This suggests the prioritization of these symptoms in the formation
25 of a severity score to characterize mild-to-moderate diarrhea in community-based study settings.

26
27 ~~Several symptoms of potential interest were not collected and therefore could not be included in our
28 analysis. Temperature, and the maximum number of instances of vomiting in a 24-hour period were not
29 collected, which limits our ability to compare our severity score to that of the 20-point Ruuska and
30 Vesikari score(11), and or the 24-point instrument proposed by Clark (9). Additionally, rectal
31 temperature and dehydration were not noted, so a comparison of the index proposed by Ericsson and
32 subsequently adapted by Jacobs et al could not be applied (25–27). These symptoms require the
33 observation of the child by a trained health worker daily, i.e. a visit to the child at the moment of illness
34 in addition to a caregiver's report. Our final severity score, which is based exclusively on information
35 extracted from the verbal report of a caregiver during twice weekly visits, may have greater utility in a
36 variety of community based study designs where daily clinical assessments are not realistic. However,
37 an ability to compare our severity score to those based on episodes observed in a clinical setting would
38 be of methodological value(28).~~

39
40 Several symptoms of potential interest were not collected and therefore could not be included in our
41 analysis, limiting our ability to compare our severity score to that of the 20-point Ruuska and Vesikari
42 score (11), the 24-point instrument proposed by Clark (9), or the index proposed by Ericsson and
43 subsequently adapted by Jacobs et al (25–27). The symptoms that were not collected are those which
44 require measurement or assessment of the child by a trained health worker, i.e. rectal temperature and
45 dehydration. Additionally, the maximum number of emeses in a 24-hour period was not noted. Our final
46 severity score, which is based exclusively on information extracted from the verbal report of a caregiver
47 during three-times weekly visits, is similar to the Vesakari and Clark scores, with the addition of anorexia
48 and the number of days with four or more liquid stools, and minus those components that depend on
49 trained observation, on the level of healthcare received (outpatient, hospitalization, etc.), or on
50 treatment decisions made by a health care professional during the episode (e.g. intravenous rehydration
51 therapy required yes/no) (Supplemental Table 1).

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For these reasons, our score may have greater utility than existing severity indices in a variety of community-based study designs where daily clinical assessments are not realistic. However, an ability to compare our score to observations made in a clinical setting would be of methodological value (28), particularly as symptoms based on maternal report are relatively subjective (although more severe symptoms do tend to be more reliably reported (29)). A severity score that includes clinical observations but could also be harmonized with a simplified version based on caregiver reported symptoms, and/or objective measures that can be used in a community-based setting, is also desirable. The association between severity and the risk of hospitalization should also be considered and assessed in a variety of settings (30,31), but because hospitalization and treatment are dependent upon access and not purely clinical need, these are better considered as outcomes that may be associated with diarrheal severity rather than components of diarrheal severity in and of themselves.

Another weakness of our study was a relatively large number of “mild” episodes with a severity score of 0-~~or 1~~, and the relatively small number of “severe” episodes with a severity score ~~>8 of 7~~ or above. Many episodes were of one or two days in duration, associated with a low (3 or 4) number of maximum stools per 24 hour period, and ~~unassociated with any other symptom, and were therefore, difficult to differentiate between,~~ although they met epidemiological criteria for diarrhea, ~~no others symptoms that might suggest systemic involvement were present. In contrast, episodes required the presence of at least three symptoms to be scored as ‘severe’ (defined here as approximately the 95th percentile).~~ These observations are consistent with the best available estimates of the proportion of categorization in mild, moderate, and severe episodes in the community setting ~~(7).~~

(7). In contrast, in the “~~high severity~~severe” category, there was a trend towards episodes of higher scores being associated with greater weight loss, i.e. an episode of severity score 15 had a greater impact than one of severity 8 (result not shown). However, because the number of episodes of greater severity was small, they were grouped in a single category. The estimated association between severe episodes and weight gain and linear growth is also correspondingly less precise. While other categorizations of each symptom within the overall score were considered, including categorizations that resulted in a greater proportion of episodes having higher scores, these were less strongly associated with weight gain than the one we present here.

In this index, we assess duration of symptoms differently than previous scores. Both the Vesikari and Clark indexes include the possibility of less than three maximum number of stools/day, which conflicts with the widely accepted definition of diarrhea in a community-based setting as requiring a minimum of three liquid or semi-liquid stools (Supplemental Table 2). We defined the bounds of an episode according to the standard epidemiological definition, and then calculated the duration of each symptom under that assumption. Instead of episode duration being included as a separate ~~variable~~ component, it was ~~evaluated for inclusion for~~ only included indirectly, through the duration of days in which each symptom was present. We believe this is important in evaluating enteric disease caused by a range of both invasive and non-invasive pathogens where the illness syndrome is diverse. In contrast, previous severity scores have been built around the ability of a symptom to discriminate between pathogens: for instance, rotavirus diarrhea is typically associated with significant vomiting and frequent stools, but relatively less fever, and the Vesakari index gives purging frequency and duration a high weight

1
2
3
4
5
6
7
8
9 accordingly¹. Unfortunately, although common bacterial enteropathogens (ETEC, *Shigella*, and
10 *Campylobacter*) were screened for in this study (21,32), rotavirus was not, and so, while validation of
11 this scoring system against the Vesikari score would be of particular interest, we are unable to do so in
12 this study.

13
14 Dysentery, as defined by caregiver-reported or laboratory technician reported visible blood, was not
15 found to be a predictor of immediate episode-associated weight loss. However, it was independently
16 predictive of poorer linear growth, a finding in agreement with other reports (29). The prevention of
17 dysenteric diarrhea, which is associated with progression to persistent diarrheal (23) and mortality (30)
18 merits prioritization. The importance of dysentery as a cause of linear growth faltering but not acute
19 weight loss suggests that multiple measurement tools for diarrheal severity may be useful. In addition
20 to acute weight loss and linear growth, factors such the likelihood of further infectious disease, the risk
21 of acute dehydration (8), and the risk of mortality, are important child health outcomes that should be
22 considered in score-building (Figure 1). The association between severity and the risk of hospitalization
23 should also be considered (31), although measures such as hospitalization, which are dependent upon
24 access and availability and not purely clinical need, vary according to local context and will need to be
25 assessed in a variety of settings (32).

26
27 We also included in our score the total number of days with four or more liquid stools. The number of
28 total liquid + semi-liquid stools, and the number of days with ≥ 4 liquid+semi-liquid stools were strongly
29 correlated with the maximum number of stools/24 hour period, while the number of days with ≥ 4
30 liquid stools was relatively less correlated with the total or maximum number of stools and was strongly
31 associated with poorer weight gain even after adjusting for total stools.

32
33 Dysentery, as defined by caregiver-reported or laboratory technician reported visible blood, was not
34 found to be a predictor of immediate episode-associated weight loss. However, it was independently
35 predictive of poorer linear growth, a finding in agreement with other reports (33). The prevention of
36 dysenteric diarrhea, which is associated with progression to persistent diarrheal (23) and mortality (34)
37 and merits prioritization. The importance of dysentery as a cause of linear growth faltering but not acute
38 weight loss also suggests that multiple measurement tools for diarrheal severity may be useful. In
39 addition to acute weight loss and linear growth, which we used here, factors such the likelihood of
40 further infectious disease, the risk of acute dehydration (8), and the risk of mortality are important child
41 health outcomes that should be considered in score-building (Figure 1).

42
43 Standardized and carefully considered measures of diarrheal severity are desirable in clinical trials,
44 intervention studies and descriptive community-based studies of diarrhea in the developing-world
45 (33), low-income settings (35), and would improve understanding of the impact of disease control
46 measures on morbidity burden. The severity score we derived here is composed of simple components
47 and allows for the meaningful classification of a diarrheal disease episode based upon the most common
48 adverse events associated with diarrhea; depressed weight gain and poorer linear growth, an

49
50
51 ¹ With a maximum of 6 points related to vomiting and a maximum of 3 related to fever.
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

improvement over earlier scores built empirically around symptom frequency. The collection of the input data for this score is highly feasible and are likely available in many extant datasets; further validation could improve the estimates of diarrhea severity and disease burden across epidemiologic settings.

Contributors

MK conceived and designed the study. MK, MPO, PPY designed the data collection tools, monitored recruitment and data collection for the study, and supervised the study. PPY managed and cleaned the data. GL designed and implemented the analysis, CFW, LEC, REB, and DAS provided guidance during the analysis, and contributed to the interpretation of data. All authors helped write and critically review the article, and all authors have approved the final version to be published and agree to be accountable for all aspects of the work. MK and GL are the guarantors.

Funding

This work was supported by the National Institutes of Health [K01-TW05717 to M.K]. G.L. was supported by a National Institutes of Health International Maternal and Child Health Training Grant [T32HD046405] (PI Dr. Joanne Katz) and a Proctor and Gamble Doctoral Dissertation Fellowship, awarded by the Johns Hopkins Bloomberg School of Public Health. The funders had no role in the collection, analysis, or interpretation of the data.

Ethical Approval

This study was approved by the Institutional Review boards of the Johns Hopkins Bloomberg School of Public Health, Baltimore, MD (IRB H.22.01.01.02.A), the US Naval Medical Research Center, Silver Springs, MD (IRB NMRCD.2002.0009), and Asociación Benéfica PRISMA, Lima, Peru (no IRB number). All participating families gave signed, informed consent before taking part in the study.

Competing Interests

We have read and understood the BMJ policy on declaration of interests and declare the following interests: None. All authors have completed the ICMJE uniform disclosure form at www.icjme.org/coi_disclosure.pdf (available on request from the corresponding author).

Declaration of Transparency

1
2
3
4
5
6
7
8
9 Gwenyth Lee confirms that this article is an honest, accurate and transparent account of the study
10 reported, that no important aspects of the study have been omitted; and that any discrepancies from
11 the study as planned have been explained.
12

13 14 Acknowledgements

15
16 We would like to thank Dr. William Pan for his contribution to the data analysis, ~~and Dr. Jamie Perin for~~
17 ~~her review of the manuscript. We would also like to thank~~ Matilda Bustos Aricara, Victoria Lopez
18 Manuyama, Marla Judith Aricari Huanari, and Lleny Amasifuen Llerena, for their hard work and
19 thoughtful contributions in the field. ~~We would also like to thank Dr. S.T. Unt for his unwavering~~
20 ~~support of the team throughout, and the study families for their generosity with their time and~~
21 ~~willingness to participate.~~
22
23

24 25 Data sharing

26
27 Raw data used in the analysis is available on request from the corresponding author at
28 mkosek@jhsph.edu. Statistical code is also available upon request.
29
30
31
32
33
34
35

36 37 References

- 38
39 1. ~~Guerrant RL, Kosek M, Moore S, Lortz B, Brantley R, Lima AAM. Magnitude and Impact of~~
40 ~~Diarrheal Diseases. Arch Med Res. 2002;33(4):351–5.~~
- 41
42 2. ~~Liu L, Johnson HL, Cousens S, Perin J, Scott S, Lawn JE, et al. Global, regional, and national causes~~
43 ~~of child mortality: an updated systematic analysis for 2010 with time trends since 2000. Lancet.~~
44 ~~Elsevier Ltd; 2012 Jun 9;379(9832):2151–61.~~
- 45
46 3. ~~Fischer-Walker CL, Perin J, Aryee MJ, Boschi-pinto C, Black RE. Diarrhea incidence in low- and~~
47 ~~middle-income countries in 1990 and 2010: a systematic review. BMC Public Health. BioMed~~
48 ~~Central Ltd; 2012;12(1):220.~~
- 49
50 4. ~~Johnston BC, Shamseer L, da Costa BR, Tsuyuki RT, Vohra S. Measurement issues in trials of~~
51 ~~pediatric acute diarrheal diseases: a systematic review. Pediatrics. 2010 Jul;126(1):e222–31.~~
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

5. Baqui AH, Black RE, Yunus M, Hoque A R, Chowdhury HR, Sack RB. Methodological issues in diarrhoeal diseases epidemiology: definition of diarrhoeal episodes. *Int J Epidemiol.* 1991 Dec;20(4):1057–63.
6. Stanton B, Clemens JD. Chronic diarrhoea: a methodologic basis for its apparent heterogeneity. *Trop Geogr Med.* 1989;41(2):100–7.
7. Lamberti LM, Fischer Walker CL, Black RE. Systematic review of diarrhea duration and severity in children and adults in low- and middle-income countries. *BMC Public Health.* 2012;12(1):276.
8. Black RE, Merson M, Huq I, Alim A, Yunus M. Incidence and Severity of Rotavirus and Escherichia Coli Diarrhoea: Implications for Vaccine Development. *Lancet.* 1981;1978–80.
9. Clark HF, Borian FE, Bell LM, Modesto K, Gouvea V, Plotkin SA. Protective effect of WC3 vaccine against rotavirus diarrhea in infants during a predominantly serotype 1 rotavirus season. *Vaccine.* 2012;158(3):570–87.
10. Flores J, Perez-schael J, Gonzales M, Garcia D, Cunto W, Chanock RM, et al. Protection against severe rotavirus diarrhoea by rhesus rotavirus vaccine in Venezuelan infants. *Lancet.* 1986;329(8538):882–4.
11. Ruuska T, Vesikari T. Rotavirus disease in Finnish children: use of numerical scores for clinical severity of diarrhoeal episodes. *Scan J Infect Dis.* 1990;22(3):259–67.
12. Schmidt W P, Arnold BF, Boisson S, Genser B, Luby SP, Barreto ML, et al. Epidemiological methods in diarrhoea studies — an update. *Int J Epidemiol.* 2011;40(6):1678–92.
13. Freedman SB, Eltorly M, Gorelick M. Evaluation of a gastroenteritis severity score for use in outpatient settings. *Pediatrics.* 2010 Jun;125(6):e1278–85.
14. Mertz HR, Beck C, Dixon W, Esquivel A, Hays RD, Shapiro MF. Validation of a new measure of diarrhea. *Digest Dis Sci.* 1995 Sep;40(9):1873–82.
15. Black RE, Allen LH, Bhutta ZA, Caulfield LE, de Onis M, Ezzati M, et al. Maternal and child undernutrition: global and regional exposures and health consequences. *Lancet. Elsevier;* 2008;371(9608):243–60.
16. Yoon P, RE B, Moulton H, Becker S. The effect of malnutrition on the risk of diarrheal and respiratory mortality in children < 2 y of age in Cebu, Philippines. *Am j Clin Nutr.* 1997 Apr;65(4):1070–7.
17. Guerrant RL, Schorling JB, McAuliffe JF, De Souza M a. Diarrhea as a cause and an effect of malnutrition: diarrhea prevents catch-up growth and malnutrition increases diarrhea frequency and duration. *Am J Trop Med Hyg. ASTMH;* 1992 Jul;47(1):28–35.
18. Richard SA, Black RE, Gilman RH, Guerrant RL, Kang G, Rasmussen ZA, et al. Wasting is associated with stunting in early childhood. *J Nutr.* 2012;142(7):1291–6.

19. — Grantham-McGregor S. A review of studies of the effect of severe malnutrition on mental development. *J Nutr. Am Soc Nutrition*; 1995;125(8):2233.
20. — Haas JD, Murdoch S, Rivera J, Martorell R. Early nutrition and later physical work capacity. *Nutr Rev*. 1996;54(2 Pt 2):S41.
21. — Kosek M, Yori PP, Pan WK, Olortegui MP, Gilman RH, Perez J, et al. Epidemiology of highly endemic multiply antibiotic resistant shigellosis in children in the Peruvian Amazon. *Pediatrics*. 2008 Sep;122(3):e541–9.
22. — Lee G, Peñataro Yori P, Paredes Olortegui M, Pan W, Caulfield L, Gilman RH, et al. Comparative effects of vivax malaria, fever and diarrhoea on child growth. *Int J Epidemiol*. 2012;41(2):531–9.
23. — Baqui AH, Black RE, Sack RB, Yunus MD, Siddique AK, Chowdhury HR. Epidemiological and clinical characteristics of acute and persistent diarrhoea in rural Bangladeshi children. *Acta Paediatr Suppl Suppl*. 1992;81(s383):15–21.
24. — Stolwijk A, Straatman H, Zielhuis G. Studying seasonality by using sine and cosine functions in regression analysis. *J Epidemiol Commun H*. 1999 Apr;53(4):235–8.
25. — Ericsson C, DuPont H, Sullivan P, Galindo E, Evans D, Evans D. Bicozamycin, A poorly absorbable antibiotic, effectively treats travelers diarrhea. *Ann Intern Med*. 1983;98(1):20.
26. — Ericsson C, Johnson P, Dupont H, Morgan D, Bitsura A, de la Cabada F. Ciprofloxacin or Trimethoprim-Sulfamethoxazole as Initial Therapy for Travelers' Diarrhea: A Placebo-Controlled, Randomized Trial. *Ann Intern Med*. 1987;106:216–20.
27. — Jacobs J, Gloyd S, Margarita Jimenez L, Crothers D. Treatment of Acute Childhood Diarrhea With Homeopathic Medicine: A Randomized Clinical Trial in Nicaragua. *Pediatrics*. 1994;93:719.
28. — Givon Lavi N, Greenberg D, Dagan R. Comparison between two severity scoring scales commonly used in the evaluation of rotavirus gastroenteritis in children. *Vaccine*. 2008;26(46):5798–801.
29. — Alam DS, Marks GC, Baqui AH, Yunus M, Fuchs GJ. Association between clinical type of diarrhoea and growth of children under 5 years in rural Bangladesh. *Int J Epidemiol*. IEA; 2000 Oct;29(5):916–21.
30. — Victora CG, Huttly SRA, Fuchs SC, Barros FC, Garenne M, Leroy O, et al. International differences in clinical patterns of diarrhoeal deaths: a comparison of children from Brazil, Senegal, Bangladesh, and India. *J Diarrhoeal Dis Res*. 1993;11(1):25–9.
31. — Walker CLF, Sack D, Black RE. Etiology of diarrhea in older children, adolescents and adults: a systematic review. *PLoS Negl Trop Dis*. 2010;4(8):e768.
32. — Seidlein L Von, Kim DR, Ali M, Lee H, Wang X, Thiem VD, et al. A multicentre study of Shigella diarrhoea in six Asian countries: disease burden, clinical manifestations, and microbiology. *PLoS Med*. 2006;3(9):1556–69.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- ~~33. Sinha IP, Altman DG, Beresford MW, Boers M, Clarke M, Craig J, et al. Standard 5: selection, measurement, and reporting of outcomes in clinical trials in children. *Pediatrics*. 2012;129(3):S146–S152.~~
1. Guerrant RL, Kosek M, Moore S, Lorntz B, Brantley R, Lima AAM. Magnitude and Impact of Diarrheal Diseases. *Arch Med Res*. 2002;33(4):351–5.
 2. Liu L, Johnson HL, Cousens S, Perin J, Scott S, Lawn JE, et al. Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000. *Lancet*. Elsevier Ltd; 2012 Jun 9;379(9832):2151–61.
 3. Fischer-Walker CL, Perin J, Aryee MJ, Boschi-pinto C, Black RE. Diarrhea incidence in low- and middle-income countries in 1990 and 2010: a systematic review. *BMC Public Health*. BioMed Central Ltd; 2012;12(1):220.
 4. Johnston BC, Shamseer L, da Costa BR, Tsuyuki RT, Vohra S. Measurement issues in trials of pediatric acute diarrheal diseases: a systematic review. *Pediatrics*. 2010 Jul;126(1):e222–31.
 5. Baqui AH, Black RE, Yunus M, Hoque A R, Chowdhury HR, Sack RB. Methodological issues in diarrhoeal diseases epidemiology: definition of diarrhoeal episodes. *Int J Epidemiol*. 1991 Dec;20(4):1057–63.
 6. Stanton B, Clemens JD. Chronic diarrhoea: a methodologic basis for its apparent heterogeneity. *Trop Geogr Med*. 1989;41(2):100–7.
 7. Lamberti LM, Fischer-Walker CL, Black RE. Systematic review of diarrhea duration and severity in children and adults in low- and middle-income countries. *BMC Public Health*. 2012;12(1):276.
 8. Black RE, Merson M, Huq I, Alim A, Yunus M. Incidence and Severity of Rotavirus and Escherichia Coli Diarrhoea: Implications for Vaccine Development. *Lancet*. 1981;1978–80.
 9. Clark HF, Borian FE, Bell LM, Modesto K, Gouvea V, Plotkin SA. Protective effect of WC3 vaccine against rotavirus diarrhea in infants during a predominantly serotype 1 rotavirus season. *Vaccine*. 2012;158(3):570–87.

10. [Flores J, Perez-schael I, Gonzales M, Garcia D, Cunto W, Chanock RM, et al. Protection against severe rotavirus diarrhoea by rhesus rotavirus vaccine in Venezuelan infants. Lancet. 1986;329\(8538\):882–4.](#)
11. [Ruuska T, Vesikari T. Rotavirus disease in Finnish children: use of numerical scores for clinical severity of diarrhoeal episodes. Scan J Infect Dis. 1990;22\(3\):259–67.](#)
12. [Schmidt W-P, Arnold BF, Boisson S, Genser B, Luby SP, Barreto ML, et al. Epidemiological methods in diarrhoea studies — an update. Int J Epidemiol. 2011;40\(6\):1678–92.](#)
13. [Freedman SB, Eltorky M, Gorelick M. Evaluation of a gastroenteritis severity score for use in outpatient settings. Pediatrics. 2010 Jun;125\(6\):e1278–85.](#)
14. [Mertz HR, Beck C, Dixon W, Esquivel A, Hays RD, Shapiro MF. Validation of a new measure of diarrhea. Dig Dis Sci. 1995 Sep;40\(9\):1873–82.](#)
15. [Black RE, Allen LH, Bhutta ZA, Caulfield LE, de Onis M, Ezzati M, et al. Maternal and child undernutrition: global and regional exposures and health consequences. Lancet Elsevier; 2008;371\(9608\):243–60.](#)
16. [Yoon P, RE B, Moulton H, Becker S. The effect of malnutrition on the risk of diarrheal and respiratory mortality in children < 2 y of age in Cebu, Philippines. Am j Clin Nutr. 1997 Apr;65\(4\):1070–7.](#)
17. [Guerrant RL, Schorling JB, McAuliffe JF, De Souza M a. Diarrhea as a cause and an effect of malnutrition: diarrhea prevents catch-up growth and malnutrition increases diarrhea frequency and duration. Am J Trop Med Hyg. ASTMH; 1992 Jul;47\(1\):28–35.](#)
18. [Richard SA, Black RE, Gilman RH, Guerrant RL, Kang G, Rasmussen ZA, et al. Wasting is associated with stunting in early childhood. J Nutr. 2012;142\(7\):1291–6.](#)
19. [Grantham-McGregor S. A review of studies of the effect of severe malnutrition on mental development. J Nutr. Am Soc Nutrition; 1995;125\(8\):2233.](#)
20. [Haas JD, Murdoch S, Rivera J, Martorell R. Early nutrition and later physical work capacity. Nutr Rev. 1996;54\(2 Pt 2\):S41.](#)
21. [Kosek M, Peñataro Yori P, Pan WK, Paredes Olortegui M, Gilman RH, Perez J, et al. Epidemiology of highly endemic multiply antibiotic-resistant shigellosis in children in the Peruvian Amazon. Pediatrics. Am Acad Pediatrics; 2008 Sep;122\(3\):e541–9.](#)
22. [Lee G, Peñataro Yori P, Paredes Olortegui M, Pan W, Caulfield L, Gilman RH, et al. Comparative effects of vivax malaria, fever and diarrhoea on child growth. Int J Epidemiol. 2012;41\(2\):531–9.](#)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

23. [Baqi AH, Black RE, Sack RB, Yunus MD, Siddique AK, Chowdhury HR. Epidemiological and clinical characteristics of acute and persistent diarrhoea in rural Bangladeshi children. Acta Paediatr Suppl. 1992;81\(s383\):15–21.](#)
24. [Stolwijk A, Straatman H, Zielhuis G. Studying seasonality by using sine and cosine functions in regression analysis. J Epidemiol Commun H. 1999 Apr;53\(4\):235–8.](#)
25. [Ericsson C, DuPont H, Sullivan P, Galindo E, Evans D, Evans D. Bicozamycin, A poorly absorbable antibiotic, effectively treats travelers diarrhea. Ann Intern Med. 1983;98\(1\):20.](#)
26. [Ericsson C, Johnson P, Dupont H, Morgan D, Bitsura A, de la Cabada F. Ciprofloxacin or Trimethoprim-Sulfamethoxazole as Initial Therapy for Travelers' Diarrhea: A Placebo-Controlled, Randomized Trial. Ann Intern Med. 1987;106:216–20.](#)
27. [Jacobs J, Gloyd S, Margarita Jimenez L, Crothers D. Treatment of Acute Childhood Diarrhea With Homeopathic Medicine: A Randomized Clinical Trial in Nicaragua. Pediatrics. 1994;93:719.](#)
28. [Givon-Lavi N, Greenberg D, Dagan R. Comparison between two severity scoring scales commonly used in the evaluation of rotavirus gastroenteritis in children. Vaccine. 2008;26\(46\):5798–801.](#)
29. [Lee G, Cama V, Gilman RH, Cabrera L, Saito M, Checkley W. Comparison of two types of epidemiological surveys aimed at collecting daily clinical symptoms in community-based longitudinal studies. Ann Epidemiol \[Internet\]. Elsevier Inc; 2010 Feb \[cited 2014 Apr 22\];20\(2\):151–8. Available from: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2837588&tool=pmcentrez&ndertype=abstract>](#)
30. [Seidlein L Von, Kim DR, Ali M, Lee H, Wang X, Thiem VD, et al. A multicentre study of Shigella diarrhoea in six Asian countries: disease burden, clinical manifestations, and microbiology. PLoS Med. 2006;3\(9\):1556–69.](#)
31. [Walker CLF, Sack D, Black RE. Etiology of diarrhea in older children, adolescents and adults: a systematic review. PLoS Negl Trop Dis. 2010;4\(8\):e768.](#)
32. [Lee G, Paredes Olortegui M, Yori PP, Black RE, Caulfield LE, Banda Chavez C, et al. Effects of Shigella, Campylobacter, and ETEC-associated Diarrhea on Childhood Growth. Ped Infect Dis J. 2014; epub ahead.](#)
33. [Alam DS, Marks GC, Baqui AH, Yunus M, Fuchs GJ. Association between clinical type of diarrhoea and growth of children under 5 years in rural Bangladesh. Int J Epidemiol. IEA; 2000 Oct;29\(5\):916–21.](#)

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
34. [Victora CG, Huttly SRA, Fuchs SC, Barros FC, Garenne M, Leroy O, et al. International differences in clinical patterns of diarrhoeal deaths: a comparison of children from Brazil, Senegal, Bangladesh, and India. J Diarrhoeal Dis Res. 1993;11\(1\):25-9.](#)
35. [Sinha IP, Altman DG, Beresford MW, Boers M, Clarke M, Craig J, et al. Standard 5: selection, measurement, and reporting of outcomes in clinical trials in children. Pediatrics. 2012;129\(S3\):S146-S152.](#)

Tables and Figures

Table 1: Association of Symptoms with Weight Gain

Caption: In the below model, age (as fractional polynomials, term1= $age^{-2} - 1.16$ and term2= $\ln(age) * age^{-2} - 0.08$), season (with sine/cosine terms), and an AR(1) covariance structure.

	Present in episode yes/no change in weight (g) associated with symptom presence	duration change in weight (g) per days present
Anorexia	-49.1 (-8.8, -9.946.6 (-87.7, -5.6) (p=0.014026)	-12.4 (-22.49 (-23.1, -2.47) (p=0.015013)
Blood in Stool (observed by Mother)	-2.1.8 (-61.47, 57.85) (p=0.952946)	-4.1.3 (-26.2, 23.7 (-30.1, 21.9) (p=0.920757)
Blood in Stool (observed by lab tech)	-10.63 (-72.58, 93.65) (p=0.802807)	N/A
Fever	-4647.9 (-8889.1, -6.5.7) (p=0.026023)	-17.4 (-33.4, -119.5 (-36.7, -2.3) (p=0.034026)
Nausea	-1.25 (-60.5, -58.28, 57.9) (p=0.970962)	-2.2 (-28.3, 23.829.6, 25.2) (p=0.866875)
Malaise	-49.4 (-84.95 (-85.0, -14.01) (p=0.006)	-9.5 (-17.8, -1.29 (-18.3, -0.4) (p=0.025022)
Mucus in Stool (observed by Mother)	-4.75 (-47.43, 38.03) (p=0.829837)	-0.1 (-14.4, 14.515.0, 15.0) (p=0.994998)
Mucus in Stool (observed by Lab tech)	0.32.9 (-34.4, -41.08, 40.6) (p=0.862879)	N/A
Stomach Pain	-13.9 (-48.89, 21.40) (p=0.427435)	-5.48 (-13.37, 2.52) (p=0.179156)
Vomiting	-56.957.0 (-109.23, -4.7) (p=0.033)	-23.2 (-4628.0, -0.5 (-52.9, 30.8) (p=0.046028)
Four or more liquid stools in a 24/hr period	-44.0 (-8043.1 (-79.6, -7.56.6) (p=0.018021)	-23.65 (-37.65, -9.65) (p=0.001)
Maximum number of stools /24 hr period (continuous)	-9.9 (-18.0, -1.8) (p=0.016)	N/A
Episode Duration (per day - continuous)	-5.1 (-12.5, 2.4) (p=0.181)	N/A

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Formatted: Font: Bold

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 2: Correlations between symptoms retained in final severity score (N=3,738915)

Symptoms are categorized [here](#) according to the manner that they are included in the final score (0 days with symptom = 0, 1-2 days with symptom=1, 3-4 days with symptom=2, 5+ days with symptom=3).

	Anorexia	Fever	Vomiting	Liquid Stools	Max Stools
Days with Anorexia	1				
Days with Fever	0.2724	1			
Days with Vomiting	0.2423	0.2430	1		
Days with >=4 Liquid Stools	0.3224	0.2527	0.1629	1	
Maximum stools/24hr period	0.2532	0.2729	0.2730	0.3438	1

Table 3: Severity Scorecard

Symptom	Category	Points
Diarrhea	>=3 liquid or semi-liquid stools per day, for 1-13 days, with gaps of no more than one day <u>two days</u>	
Fever	No Fever	+0
	Fever for 1-2 days	+1
	Fever for 3-4 days	+2
	Fever for 5+ days	+3
Anorexia	No Anorexia	+0
	Anorexia for 1-2 days	+1
	Anorexia for 3-4 days	+2
Vomiting	No Vomiting	+0
	Vomiting for 1-2 days	+1
	Vomiting for 3-4 days	+2
	Vomiting for 5+ days	+3
Liquid Stools	No days with >=4 liquid stools	+0
	1-2 days with >=4 liquid stools	+1
	3-4 days with >=4 liquid stools	+2
	5+ days with >=4 liquid stools	+3
Maximum number of stools in a 24 hour period during the episode	3	+0
	4-5	+1
	6-7	+2
	>=8	+3
TOTAL		0-15

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60**Table 4: Association between Severity Score and change in Weight and Weight-for-Height**

The association between incident episodes of diarrheal classified as low (score 0-4), medium severity (score 2-71-6) and high severity (score >=87) on the change in weight and weight-for-height Z over 1-month intervals, is shown below. Age (same fractional polynomials as in symptom-specific models) and season (sine and cosine terms) were also adjusted for (beta coefficients not shown).

	1-month change in Weight (g)	1month change in WHZ (Z-score)
Low Severity	ref	ref
Medium Severity	-49.3 (-84.8, -13.825.4 (-63.0, 12.2) (p=0.007186)	-0.049 (-0.090, -0.008 (-0.052, 0.036) (p=0.020720)
High Severity	-133.0 (-223.132.2, -42.8 (- 213.6, -50.7) (p=0.004001)	-0.180 (-0.285.2, -0.75.7171 (-0.266, - 0.077) (p=<0.001)

Table 5: Association between Severity Score and Linear Growth

Formatted: Tab stops: 5.18", Left

The association between incident episodes of diarrheal classified as low (score 0-4), medium severity (score 5-7) and high severity (score >=8) on the change in height and HAZ over 9-month intervals, is shown below. Age (fractional polynomials used to adjust for age in the height model are term1= $age^{-2} - 0.56$ and term3= $\ln(age) * age^3 - 2.41$), season (sine and cosine terms), stunting, and WHZ (categorized as >0, 0 to -1, and <-1) were also adjusted for (beta coefficients not shown). In the HAZ model, fractional polynomials for age are $age^{-2} - 1.80$ and $-\ln(age) * age^2 - 0.53$.

	9mo change in Ht (cm)	9mo change in HAZ (Z-score)
Low-severity episodes (incidence)	-0.021014 (-0.043042, 0.001015) (p=0.057348)	-0.004001 (-0.11012, 0.003009) (p=0.299755)
Medium-severity episodes	-0.041035 (-0.065056, -0.016014) (p=0.001)	-0.010009 (-0.19016, -0.001) (p=0.022025)
High-severity episodes	-0.003011 (-0.069067, 0.074044) (p=0.936690)	-0.011008 (-0.036028, 0.015012) (p=0.423439)
Episodes of dysentery	-0.113112 (-0.189, -0.038036) (p=0.003004)	-0.034033 (-0.062061, -0.007006) (p=0.013018)

1
2
3
4
5
6
7
8
9 **Figure 1: Conceptual Diagram of Idealized Severity Score**


10
11
12 **Figure 2: Example of Severity Score Applied to an Episode:** A 6-day episode with fever on 3 days (+2),
13 anorexia on 0 days (+0), vomiting on 1 day (+1), a maximum total number of stools/day of 6 (+2) and a
14 total of 3 days with 4 or more liquid stools (+2) = total severity score of 7.
15
16

17
18 **Figure 2: Episodes included in the analysis**

19 **Figure 3: Distribution of Symptoms:** Out of all episodes (n=3,738915)

20
21
22
23 **Figure 4: Histogram of severity score distribution:** The y-axis (frequency) indicates the number of
24 episodes assigned to the score (N= 3,738915).
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Study Type	Community Setting		Healthcare Setting	
Type of diarrhea study will find	Mild	Moderate	Severe	
Episodes can be gradated by symptoms such as:	stomach pain, anorexia	Moderate dehydration, dysentery	Severe dehydration, need for IV hydration	
"Severity index" should correlate to:	Poorer growth, risk of MN deficiency, risk of future illness		Risk of short-term mortality	

Conceptual Diagram of Idealized Severity Score
190x142mm (300 x 300 DPI)

Review only


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Episodes included in the analysis
190x142mm (300 x 300 DPI)

ew only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Distribution of Symptoms: Out of all episodes (n=3,915)
279x186mm (300 x 300 DPI)

Review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 4: Histogram of severity score distribution: The y-axis (frequency) indicates the number of episodes assigned to the score (N= 3,915).
86x57mm (300 x 300 DPI)

view only

Supplemental Table 1: Severity score calculation applied to several examples:

	Sun	Mon	Tues	Wed	Thurs	Fri	Sat
Fever	no	YES	YES	YES	no	no	no
Anorexia	no	no	no	no	no	no	no
Vomiting	no	no	YES	no	no	no	no
Total Number of solid stools	0	0	0	1	0	0	0
Total Number of semi-liquid stools	3	4	4	5	6	3	2
Total number of Liquid stools	0	0	4	4	4	0	0
Total stools	3	4	8	10	10	3	2

(i) A 6-day episode with fever on 3 days (+2), anorexia on 0 days (+0), vomiting on 1 day (+1), a maximum total number of stools/day of 10 (+3) and a total of 3 days with 4 or more liquid stools (+2) = total severity score of 8.

	Sun	Mon	Tues	Wed	Thurs	Fri	Sat
Fever	no	no	no	no	no	no	no
Anorexia	no	no	YES	no	no	no	no
Vomiting	no	no	no	no	no	no	no
Total Number of solid stools	2	2	0	0	1	2	1
Total Number of semi-liquid stools	0	2	2	1	0	0	0
Total number of Liquid stools	0	0	1	2	0	0	0
Total stools	2	4	3	3	1	2	1

(i) A 2-day episode with no fever (+0), anorexia on 1 days (+0), no vomiting (+0), a maximum total number of stools/day of 3 (+0) and no days with 4 or more liquid stools (+0) = total severity score of 1.

	Sun	Mon	Tues	Wed	Thurs	Fri	Sat
Fever	no	no	no	no	no	no	no
Anorexia	no	no	no	no	no	no	no
Vomiting	no	no	no	no	YES	YES	no
Total Number of solid stools	3	2	1	0	0	1	0
Total Number of semi-liquid stools	0	0	3	3	2	3	0
Total number of Liquid stools	0	0	0	0	0	0	0
Total stools	3	2	4	3	2	4	0

(ii) A 4-day episode (Tues-Fri) with no fever (+0), no anorexia (+0), two days of vomiting (+1), a maximum total number of stools/day of 4 (+1) and no days with 4 or more liquid stools (+0) = total severity score of 2.

Supplemental Table 2: Comparison of Severity Scores

Direct Observation (DO) or caregiver Report (CR)	Score component	Vesakari (11)	Clark (9)	Modified Vesikari (13)	Our Score	Scoring
Non-specific						
CR	Duration of Diarrhea	1-4 days	1-4 days	1-4 days	-	1
		5 days	2-7 days	5 days	-	2
		>=6 days	>=8 days	>=6 days	-	3
CR	Max number of stools /day	1-3	2-4	1-3	4-5	1
		4-5	5-7	4-5	6-7	2
		>=6	>=8	>=6	>=8	3
CR	Duration of >=4 Liquid Stools (days)	-	-	-	1-2 days	1
		-	-	-	3-4 days	2
		-	-	-	>=5 days	3
Vomiting						
CR	Duration of vomiting (days)	1 day	1-2 days	1 day	1-2 days	1
		2 days	3-5 days	2 days	3-4 days	2
		>=3 days	>=6 days	>=3 days	>=5 days	3
CR	Number of emeses/day	1	1-3	1	-	1
		2-4	4-6	2-4	-	2
		>=5	>=7	>=5	-	3
Fever						
CR	Duration of fever (days)	-	1-2 days	-	1-2 days	1
		-	3-4 days	-	3-4 days	2
		-	>=5 days	-	>=5 days	3
DO	Temperature / Rectal Temperature	37.1-38.4°C	38.1-38.2°C	37.1 – 38.4°C	-	1
		38.5-38.9°C	38.3-38.7°C	38.5 – 38.9°C	-	2
		>= 39.0°C	38.8°C	>=39.0°C	-	3
Dehydration / Liquid Stools						
DO	Dehydration	-	-	-	-	1
		1-5%	-	-	-	2
		>=6%	-	-	-	3
Behavioral Signs						
CR	Behavioral signs	-	irritable/less playful	-	-	1
		-	lethargic/listless	-	-	2
		-	seizure	-	-	3
CR	Behavioral signs (duration)	-	1-2 days	-	-	1
		-	3-4 days	-	-	2
		-	>=5 days	-	-	3
CR	Anorexia	-	-	-	1-2 days	1
		-	-	-	3-4 days	2
		-	-	-	>=5 days	3
Treatment						
	Treatment	Rehydration	-	Rehydration	-	1
		Hospitalization	-	Hospitalization	-	2
	Health care provider visits	-	-	Outpatient	-	2
		-	-	E.D.	-	3
Total		20 points	24 points		15	

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only